

Review

Open Access

Regulation of the retinoblastoma proteins by the human herpesviruses

Adam J Hume and Robert F Kalejta*

Address: Institute for Molecular Virology and McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706-1596, USA

Email: Adam J Hume - hume@wisc.edu; Robert F Kalejta* - rfkalejta@wisc.edu

* Corresponding author

Published: 15 January 2009

Received: 8 January 2009

Cell Division 2009, **4**:1 doi:10.1186/1747-1028-4-1

Accepted: 15 January 2009

This article is available from: <http://www.celldiv.com/content/4/1/1>

© 2009 Hume and Kalejta; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Viruses are obligate intracellular parasites that alter the environment of infected cells in order to replicate more efficiently. One way viruses achieve this is by modulating cell cycle progression. The main regulators of progression out of G₀, through G₁, and into S phase are the members of the retinoblastoma (Rb) family of tumor suppressors. Rb proteins repress the transcription of genes controlled by the E2F transcription factors. Because the expression of E2F-responsive genes is required for cell cycle progression into the S phase, Rb arrests the cell cycle in G₀/G₁. A number of viral proteins directly target Rb family members for inactivation, presumably to create an environment more hospitable for viral replication. Such viral proteins include the extensively studied oncoproteins E7 (from human papillomavirus), E1A (from adenovirus), and the large T (tumor) antigen (from simian virus 40). Elucidating how these three viral proteins target and inactivate Rb has proven to be an invaluable approach to augment our understanding of both normal cell cycle progression and carcinogenesis. In addition to these proteins, a number of other virally-encoded inactivators of the Rb family have subsequently been identified including a surprising number encoded by human herpesviruses. Here we review how the human herpesviruses modulate Rb function during infection, introduce the individual viral proteins that directly or indirectly target Rb, and speculate about what roles Rb modulation by these proteins may play in viral replication, pathogenesis, and oncogenesis.

Background

The members of the retinoblastoma family of tumor suppressors, Rb, p107 and p130, are transcriptional corepressors that regulate both differentiation and cell cycle progression. Detailed reviews on genetic and molecular analysis of the Rb pathway in normal and cancerous cells are numerous [1-6] so here we will only briefly introduce this pathway prior to describing how it is manipulated by the human herpesviruses.

In the G₀ and G₁ phases of the cell cycle the active, hypophosphorylated form of Rb binds to transcription factors of the E2F family [7-9]. Through heterodimerization with the DP proteins, E2Fs bind to promoters and control the transcription of genes that are involved in many important cellular functions including cell cycle progression [2,10], DNA replication [11,12], the DNA damage response [13], apoptosis [14-18], differentiation and development [19-21], senescence [22], and angiogenesis [23]. Rb, which itself is an E2F-responsive gene [24],

binds to E2Fs at these promoters to actively repress transcription by blocking the E2F activation domain, and by recruiting histone-modifying enzymes such as histone deacetylases (HDACs) [25-28] and chromatin remodeling proteins such as the members of the hSWI/SNF complex [29-31]. There are multiple E2F proteins, some considered mainly as transcriptional repressors, and others with more prominent roles as transcriptional activators.

Many cellular and viral proteins interact with the pocket domain of Rb [32] that consists of A and B subdomains and affords a large surface area to support strong and specific interactions. One common amino acid sequence found in proteins that interact with the Rb pocket is the LxCxE motif [25,26,33-35]. More than twenty cellular proteins such as HDACs, and a number of viral proteins interact with Rb in an LxCxE-dependent manner [35-37]. The Rb-binding LxCxE motif interacts with a site within the Rb pocket termed the cleft region. The E2F proteins do not contain LxCxE motifs and bind to a distinct site within the Rb pocket domain, allowing Rb to interact with both an E2F and HDAC simultaneously to repress transcription of E2F-responsive promoters.

HDAC-Rb-E2F complexes are disrupted during the natural progression of cells out of G₀, through G₁, and into the S phase. In a sequential and coordinated fashion, different cyclin proteins are expressed and they bind to and activate a family of cyclin-dependent kinases (Cdks). Certain cyclin/Cdk complexes control cell cycle progression, whereas others modulate the function of the RNA Polymerase II transcriptional complex [38,39]. Small molecule inhibitors of Cdk activity often inhibit multiple members of both the "cell cycle" Cdks and the "transcription" Cdks [40,41], so prescribing the effects of these inhibitors solely to modulation of cell cycle processes must be done judiciously. The Rb protein is one of the main "cell cycle" Cdk substrates, containing 16 putative Cdk phosphorylation sites. Hyperphosphorylation of Rb by a series of cyclin/Cdk pairs causes the disruption of HDAC-Rb-E2F complexes [2,5,6,10,30,42-45], allowing for the activation of E2F-responsive genes and the subsequent progression of cells through G₁ and into the S phase. Phosphorylation at any one site is insufficient to disassemble complexes between Rb and its binding proteins, whereas the accumulation of multiple phosphorylations appears to be necessary for complex disruption [43,44].

Cyclins D, E and A, in that order, are the targeting modules that direct the Cdks to phosphorylate different subsets of Cdk consensus sites on Rb. The D-type cyclin proteins have both an LxCxE motif and a region termed the hydrophobic patch that contribute to both substrate and substrate site specificity [46-48]. Cyclins E and A con-

tain a hydrophobic patch but lack LxCxE motifs. As mentioned above, the LxCxE motif binds within the cleft domain of Rb [34,37]. The hydrophobic patch binds to RxL motifs located within the C-terminus of Rb [49].

Because the phosphorylation of Rb by cyclin/Cdks represents a critical juncture in the control of cell cycle progression, this is a tightly regulated process. Multiple levels of regulation exist that include temporal cyclin expression, activating and inhibitory phosphorylation of Cdks, and the direct binding and inhibition of cyclin/Cdk complexes by two classes of small proteins termed the cyclin-dependent kinase inhibitors (Ckis) [50,51]. Additionally, Rb must return to a hypophosphorylated form during mitosis so that the cell cycle can be reset. This is achieved by the action of protein phosphatase I (PPI) [52-54]. Although there is little evidence that Rb is regulated by degradation during normal cell cycle progression, the over expression of the cellular protein gankyrin can result in Rb degradation [55] through a process that requires an intact LxCxE motif of gankyrin [56].

The pathway controlled by Rb is thought to be inactivated in most if not all human cancers [2,57]. Common mechanisms of pathway disruption include the over-expression and stabilization of cyclin D [1,58,59], inactivation of the Cki p16 [60,61], or the expression of a viral oncoprotein [62]. Certain cancers also have activating Cdk mutations [63,64], Rb loss or mutation [65], or gankyrin over-expression [55]. The other members of the Rb family, p107 and p130, also regulate E2F-mediated gene expression and are targets of the Cdks. But whereas Rb is present throughout the cell cycle, p107 and p130 each have a more limited window of expression. The p130 protein is found predominantly in G₀ cells [66,67], is rapidly phosphorylated upon entry into G₁ [66,68], and swiftly degraded following phosphorylation [69]. The p107 protein is expressed as cells begin to enter the S phase [67,70]. While Rb is often mutated in human cancers and thus is considered a true tumor suppressor protein, p130 is infrequently mutated [71-76], and no p107 mutations in human cancers have been identified.

DNA tumor viruses inactivate Rb

Cells must synthesize large amounts of DNA to replicate their genomes during the cell division cycle. Both enzymes that synthesize or metabolize deoxynucleotides, as well as enzymes that directly or indirectly facilitate deoxynucleotide polymerization are required for DNA synthesis. The coordinated production of these required enzymes is achieved by placing them under the control of the E2F transcription factors that in turn are regulated by Rb. Because viruses with DNA genomes must also synthesize significant quantities of this nucleic acid during their productive, lytic replication phases, many have evolved

ways to modulate the Rb-E2F pathway. Viral inactivation of Rb has been most extensively studied through examining the relevant transforming oncoproteins of the DNA tumor viruses, namely the Adenovirus E1A protein, the Papillomavirus E7 protein, and the Simian Virus 40 (SV40) large tumor (T) antigen. Many excellent reviews of these proteins have been published [77-79]. While the focus of this review is herpesvirus proteins that modulate the Rb pathway, a brief description of the DNA tumor virus proteins that also accomplish this task is presented to provide a platform for comparison and contrast.

Adenovirus E1A contains an LxCxE motif (the conserved region 2 (CR2) domain) that interacts in the Rb cleft [80-82], and a second motif (CR1) that competes with E2F for binding to Rb [80-82]. In this manner, E1A disrupts complexes between the E2Fs and all three Rb family members. E1A expression stimulates cell cycle progression and cooperates with other viral or cellular oncogenes to transform cells. For many years no association between adenoviral infection and human cancers could be identified, but a recent study has observed a link between fetal adenoviral infections and childhood acute lymphoblastic leukemia [83].

The human papillomavirus encoded E7 also contains an LxCxE motif, binds to all three Rb proteins, and induces their degradation through the ubiquitin-proteasome pathway [84-88]. In addition to the LxCxE domain, N-terminal sequences of unknown function are required for E7-induced Rb degradation [89]. The exact mechanism of degradation has not yet been determined. It was initially speculated that E7-mediated degradation occurred through a direct interaction with the proteasome because E7 was found to bind to the S4 subunit of the 26S proteasome [90]. However, E7 mutants that fail to bind S4 still induce Rb degradation [87]. Recently, E7 has been found to associate with an active cullin 2-based cellular ubiquitin ligase complex [91], thus it is possible that E7 redirects this cellular complex to ubiquitinate Rb. While infection with some papillomavirus genotypes (termed high risk) can lead to cervical cancer, infection with other genotypes (low risk) does not [87]. The E7 proteins from high risk papillomavirus subtypes efficiently bind and degrade Rb, and cooperate with other viral or cellular oncoproteins to transform cells [87]. E7 proteins from low risk HPV fail to transform cells but still bind and degrade Rb, although with lower efficiency than the high risk HPV E7 proteins [92].

SV40 T Antigen contains an LxCxE motif, binds to all three Rb proteins [93-95], and disrupts Rb-E2F complexes [96-98]. An additional T antigen domain with sequence homology to the cellular chaperone DNA J is also required for T antigen inactivation of all three Rb proteins

[99,100], and for dephosphorylation of p107 and p130 [98,100,101]. The role of T antigen-mediated dephosphorylation of p107 and p130 is not understood. SV40 has never been definitively associated with human tumors, although studies continue to examine a potential role for SV40 infection via contaminated polio vaccines in mesotheliomas [99,102,103].

These three viral proteins represent two distinct mechanisms of Rb inactivation: steric disruption of Rb-E2F complexes and Rb degradation. Herpesviruses encode proteins that use these, as well as other novel (direct and indirect) mechanisms to inhibit Rb family member function (Figure 1). The study of E1A, E7, and T Antigen has proven to be invaluable for the understanding of both the replication and pathogenesis of the viruses that encode them, as well as to the normal regulation of the Rb-E2F pathway. The study of herpesvirus-encoded proteins that modulate Rb through novel mechanisms should therefore also lead to a better understanding of both herpesviral replication and pathogenesis, as well as Rb family protein functional regulation during cell cycle progression and oncogenesis.

Human herpesviruses

Prior to the genomics era, herpesviruses [104] were easily distinguishable because of their characteristic morphology [105,106]. Genome-containing icosahedral capsids are surrounded first by an amorphous layer of proteins termed the tegument, and subsequently by a lipid envelope. Viral glycoproteins in the virion envelope mediate fusion with, and entry into cells. Both the capsid and tegument are released into the cytoplasm. Tegument proteins modulate host cell processes even before the production of newly synthesized viral proteins from the infecting genomes, and help deliver the capsid along microtubules to the nuclear pore complex, where the genome is injected into the nucleus [107]. The linear, double-stranded DNA genome circularizes within the nucleus. Herpesvirus genomes [108,109] range in size from 120-kb and approximately 70 genes for Varicella Zoster Virus (VZV) to 235-kb and approximately 170 genes for human cytomegalovirus (HCMV). To start a productive, lytic replication cycle [110,111], a temporal and sequential cascade of immediate early (IE), early (E) and late (L) gene expression is initiated [104]. Viral DNA replication produces long concatamers that are packaged as unit length linear genomes into capsids within the nucleus. Newly formed capsids traverse the double nuclear envelope through an envelopment, de-envelopment pathway, acquire their tegument proteins and envelopes at cytoplasmic assembly sites derived from golgi membranes, and then exit the cell by the exocytosis of virion containing vesicles [104]. During latency, viral genomes are maintained as episomes (they generally do not integrate into host chromosomes), significantly fewer viral genes are expressed (the number




Figure 1
Mechanisms used by different classes of human herpesviruses to modulate the Rb-E2F pathway. See text for details. α . HSV-1 prevents Rb phosphorylation and keeps cellular Cdk's inactive, likely through the downregulation of cyclin proteins and the mislocalization of Cdk's. VZV infected cells display Cdk activity even though p21 and p27 are induced. However, Rb remains unphosphorylated through an uncharacterized mechanism. β . HCMV infected cells show a lack of hypophosphorylated Rb and high levels of hyperphosphorylated Rb, due to both pp71-mediated degradation and UL97-mediated phosphorylation. IE2 can also directly activate E2F-responsive genes. γ . EBV has multiple proteins (Z, R, LMP-1, EBNA-2,-3C,-5) that could lead to the phosphorylation of Rb by cellular Cdk's, and/or may directly phosphorylate Rb through the function of the viral kinase, BGLF-4. KSHV can activate the Rb pathway by LANA-mediated disruption of Rb-E2F complexes, or by direct phosphorylation of Rb through the action of the v-cyclin and/or the ORF36 proteins.

varies between the different viruses), and no infectious virions are produced. Latent infections can be reactivated to allow for the new production of infectious virions decades after the primary infection.

During lytic replication and in reactivating latent infections, herpesviruses must synthesize large quantities of viral DNA. The analysis of DNA content in herpesvirus-infected cells by flow cytometry indicates that cellular genome equivalents of viral DNA are produced in these cells. Therefore, herpesviruses must either rely on their own viral machinery for the enzymes required for nucleotide biosynthesis, metabolism, and polymerization (Fig. 2), or induce the accumulation of the cellular enzymes responsible for those same activities (Fig. 3). As many of those cellular enzymes are encoded by E2F-responsive genes, and as E2F-mediated gene expression is controlled in large part by the Rb proteins, this family of tumor suppressors is likely to be a critical target for the subset of herpesviruses that rely on cellular nucleotide biosynthetic enzymes and other DNA replication-related enzymatic functions for their replication.

The eight herpesviruses that infect humans are classified into three families, the alpha-, beta-, and gammaherpesviruses (Fig. 4). Six of the eight human herpesviruses infect the vast majority of adults (the exceptions are HSV-2 and KSHV; see below for details). For each of these viruses, we will briefly describe the clinical manifestations of infection, discuss in detail the fates and functions of the Rb proteins in infected cells, and end with what we consider to be timely and relevant questions for future exploration.

Alphaherpesviruses

The human alphaherpesviruses [112,113] include Herpes Simplex Virus Type 1 (HSV-1, HHV-1 (Human Herpesvirus 1)), HSV-2 (HHV-2), and Varicella Zoster Virus (VZV, HHV-3). Both primary and reactivated infections with HSV-1 typically cause oral lesions (cold sores), while HSV-2 infections generally cause genital lesions although each of these viruses can infect either location. Primary infection with VZV causes varicella (chicken pox) and reactivation of latent infections causes zoster (shingles). HSV-1 and VZV are very common infections, but HSV-2 infects only about 8% of the population [114]. Alphaherpesviruses carry out productive, lytic replication in epithelial cells, and establish latent infections in sensory neurons. Neuroinvasiveness and their relatively rapid lytic replication cycle are defining characteristics of the alphaherpesviruses.

Herpes simplex virus type 1 and 2

Cells infected with HSV-1 accumulate in the G1 phase of the cell cycle [115-117]. Serum-arrested (G0) cells do not enter the S phase after infection, and G0 cells simultaneously infected and stimulated with serum also fail to enter the S phase [115-118]. In these HSV-1 infected, G1 arrested cells, the steady-state levels of Rb do not detectably change and the protein is found in a hypophosphorylated state bound to E2F proteins [116,118].

Inhibition of Rb phosphorylation in HSV-1 infected cells

The viral ICP27 protein (the 27th infected cell protein observed) is required to prevent the phosphorylation of Rb in HSV-1 infected cells [119]. ICP27 is a multifunctional immediate-early protein that modulates gene

	HSV-I	HSV-II	VZV	HCMV	HHV-6	HHV-7	EBV	KSHV
DNA replication machinery								
DNA polymerase	UL30	UL30	ORF28	UL54	U38	U38	BALF5	ORF9
DNA polymerase processivity subunit	UL42	UL42	ORF16	UL44	U27	U27	BMRF1	ORF59
origin-binding protein, helicase	UL9	UL9	ORF51	UL84	U73	U73	Zta	K8/K-bZIP
helicase-primase ATPase subunit	UL5	UL5	ORF55	UL105	U77	U77	BBLF4	ORF44
helicase-primase subunit C	UL8	UL8	ORF52	UL102	U74	U74	BBLF2/BBLF3	ORF40/41
helicase-primase RNA pol subunit B, primase	UL52	UL52	ORF6	UL70	U43	U43	BBLF1	ORF56
single strand DNA binding protein	UL29	UL29	ORF29	UL57	U41	U41	BALF2	ORF6
origin-binding protein / priming	-	-	-	-	-	-	-	ORF50/Rta
Nucleotide biosynthesis								
thymidine/nucleoside kinase	UL23	UL23	ORF36	-	-	-	BXLF1	ORF21
ribonucleotide reductase large subunit	UL39	UL39	ORF19	UL45**	U28**	U28**	BORF2	ORF61
ribonucleotide reductase, small subunit	UL40	UL40	ORF18	-	-	-	BaRF1	ORF60
deoxyuridine triphosphate nucleotidohydrolase	UL50	UL50	ORF8	UL72**	U45**	U45**	BLLF3	ORF54
uracil-DNA glycosidase	UL2	UL2	ORF59	UL114	U81	U81	BKRF3	ORF46
dihydrofolate reductase	-	-	-	-	-	-	-	ORF2
thymidylate synthetase	-	-	ORF13	-	-	-	-	ORF70
Drug activation								
nucleoside analog kinase	UL23	UL23	ORF36, ORF47	UL97	U69	U69?	BGLF4, BXLF1	ORF21, ORF36

** catalytically inactive

Figure 2
Genes for DNA replication machinery and nucleotide biosynthesis encoded by the human herpesviruses. Listed are the virally encoded genes involved or implicated in viral DNA replication (top), nucleotide biosynthesis (middle) and activation (by phosphorylation) of the nucleoside analogs (bottom) employed as anti-herpesviral drugs for the alpha- (yellow), beta- (blue) and gamma- (green) herpesviruses. Note the striking lack of nucleotide biosynthetic enzymes encoded by the betaherpesviruses.

Gene	Gene symbol	HSV-1	HCMV	KSHV
<i>thymidine kinase</i>	<i>TK1</i>	Grey	Red	Green
<i>ribonucleotide reductase</i>	<i>RRM2</i>	Grey	Red	Grey
<i>dUTPase</i>	<i>DUT</i>	Grey	Green	Grey
<i>uracil DNA glycosidase</i>	<i>UNG</i>	Grey	Red	Grey
<i>dihydrofolate reductase</i>	<i>DHFR</i>	Grey	Green	Green
<i>thymidylate synthetase</i>	<i>TYMS</i>	Green	Grey	Green
adenylate kinase	<i>AK1</i>	Grey	Grey	Grey
nucleoside diphosphate kinase	<i>NME7</i>	Grey	Grey	Grey
PRPP amidotransferase	<i>PPAT</i>	Green	Red	Grey
CTP synthase	<i>CTPS</i>	Grey	Red	Grey
FGAM synthase	<i>PFAS</i>	Grey	Grey	Grey

Figure 3

Modulation of the steady-state levels of mRNAs for selected nucleotide biosynthetic enzymes by the different classes of human herpesviruses. Microarray data for virus-infected cells was mined to illustrate the extent to which cellular nucleotide biosynthetic enzymes were activated upon infection with the indicated viruses. See text for a detailed discussion. HSV-1 infection of mouse embryonic fibroblasts at 4, 8, and 12 hours post infection (hpi) [317], left lane. HSV-1 infection of rat superior cervical ganglia neurons at 6, 12, and 24 hpi (Szpara and Enquist, personal communication), right lane. HCMV infection of human foreskin fibroblasts at 20, 24, and 48 hpi [316]. KSHV infection and reactivation of endothelial cells at 24, 37, and 48 hpi [315]. Red, up-regulated 2-fold or more in at least two out of three time points. Green, down-regulated 2-fold or more in at least two out of three time points. Black, any changes were less than 2-fold. Grey, not analyzed/not found. In cases where more than one probe set was present, fulfillment of above criteria by any one probe set was sufficient.

expression at multiple levels including transcription, mRNA processing, and translation [120]. Along with the tegument-incorporated virion host shut off (VHS) protein (UL41, the 41st gene in the unique long region of the genome) that degrades mRNAs [121], ICP27 plays a role in the inhibition of host protein synthesis by inhibiting mRNA splicing [122-124] (this has little effect on viral gene expression because most herpesvirus genes are not spliced). Host shut off likely contributes to, but is not sufficient for the ability of ICP27 to inhibit Rb phosphorylation [119]. The ICP0 protein has been shown to arrest cell cycle progression [125,126] although the role it plays in Rb hypophosphorylation upon HSV-1 infection has not been examined. Likewise, the combined roles that ICP0 and ICP27 may play in the G1 arrest instituted by HSV-1 have not been resolved.

Infection with an ICP27-null virus results in Rb phosphorylation [119] although the kinase(s) responsible for this phosphorylation has not been identified. Likely candidates, however, would include the cellular kinase complexes composed of cyclin D/Cdk4,6 and cyclin E/Cdk2, as these complexes are known to phosphorylate Rb in uninfected cells. These kinases are inactive in wild-type HSV-1 infected cells for multiple reasons, such as the failure of cyclins to accumulate [115,117], the sequestering of Cdks in the cytoplasm [117], and the inhibition of preex-

isting cyclin/Cdk complexes by an unresolved mechanism that may be independent of the Cki proteins [117]. Further experiments performed in cells infected with ICP27 or ICP0-null HSV-1 could help define how Rb is regulated upon HSV-1 infection. It would be particularly interesting to determine if small molecule Cdk inhibitors such as roscovitine or flavopiridol have any effect on Rb phosphorylation in cells infected with these mutant viruses.

Curiously, one report indicated that Rb phosphorylation is induced by HSV-2 infection even though progression of infected cells into the S phase was inhibited [127], a situation analogous to HCMV infection (see below). Cyclin A/Cdk1 was implicated in the phosphorylation of Rb in HSV-2 infected cells [127]. A subsequent report was unable to confirm this, but found that both HSV-1 and HSV-2 did not induce Rb phosphorylation after infection of quiescent cells, and caused Rb dephosphorylation after infection of cycling cells [115]. A novel under-phosphorylated form of Rb in HSV infected cells (termed b') has been observed [115,117] although it is unclear whether this represents a novel site of phosphorylation or just an intermediately phosphorylated form. It is unlikely, however, that Rb-b' explains the different conclusions of the independent HSV-2 studies [115,127]. Thus, more work is needed to determine if Rb is regulated differently after infection with these two similar viruses and, if so, how




Figure 4
Expression of nucleotide biosynthetic enzymes during the lytic and latent phases of different classes of human herpesviruses. See text for details. α . During lytic infection HSV-1 does not induce the expression of cellular NBEs (nucleotide biosynthetic enzymes), and thus appears to rely on viral NBEs. It is unclear if the shutoff of host protein synthesis contributes to the absence of host NBE expression. During latency, viral genomes are not replicated and thus no NBEs appear to be required. Reactivation is assumed to be similar to lytic infection with a reliance on viral NBEs. β . During lytic infection HCMV robustly activates the expression of cellular NBEs, likely because it does not encode a full complement of viral NBEs. Reliance on NBEs during latency is not known because it is unclear if the viral genome replicates. However if viral genomic replication occurs, it is likely that cellular NBEs provide the needed nucleotides. Reactivation is assumed to be similar to lytic infection with a reliance on cellular NBEs. γ . During lytic infection EBV inactivates Rb and expresses its own NBEs, so both cellular and viral NBEs might be utilized. Note the shutoff of host protein synthesis during KSHV infection would appear to imply that viral NBEs play a more prominent role in KSHV lytic infection. During latency, viral proteins inactivate Rb and viral NBEs aren't expressed, implying a reliance on viral NBEs. Reactivation is assumed to be similar to lytic infection with a reliance on viral NBEs (for KSHV) or both viral and cellular NBEs (for EBV).

that differential regulation affects viral replication, tropism, or pathogenesis.

The preponderance of evidence supports a model in which Rb is held in a hypophosphorylated (i.e. active) state in HSV infected cells, possibly because G1 cyclin/Cdk activity is low or absent. Interestingly, fibroblasts derived from mouse Rb -/- embryos (Rb-null MEFs) show no defects in supporting HSV-1 replication [128]. This

indicates either that active Rb is not required for HSV-1 infection, or that other pocket proteins (p107 or p130) can compensate for Rb loss in these cells.

A critical role for p130 during HSV-1 infection

In quiescent (G0) cells, p107 is absent but upon serum stimulation its expression is induced as cells enter the S phase. HSV-1 infection coincident with serum stimulation inhibits the accumulation of the p107 protein [117].

In asynchronous cells infected with HSV-1, p107-E2F complexes were found to accumulate [118,129], a finding consistent with dephosphorylation such as that seen with Rb and p130 [117]. Similar to Rb, p107 function doesn't appear to be vital to HSV-1 lytic replication as p107-null MEFs support efficient viral replication [128].

HSV-1 infection inhibits the phosphorylation and subsequent degradation of the p130 protein that is observed as G0 cells enter the G1 phase, and causes a re-accumulation of hypophosphorylated p130 within infected G1 cells [117]. Contrary to what was observed with Rb and p107, p130 appears to be critical for lytic HSV-1 replication [128]. In p130-null MEFs, HSV-1 shows a 10- to 100-fold growth defect. A delay in IE gene expression was observed in these cells, as well as subsequent defects in viral DNA replication and late gene expression. The IE protein ICP0 was almost undetectable in these cells [128]. Because ICP0 is a critical regulator of HSV-1 lytic replication [130,131], it would be interesting to determine if ectopic expression of ICP0 corrected the HSV-1 replication defects observed in p130-null MEFs. HSV-1 infection failed to downregulate Cdk2 activity in p130-null MEFs [128]. When these cells were synchronized in early G1 (where Cdk2 activity is low), viral replication was partially rescued [117]. This is interesting because in addition to its ability to regulate E2F-mediated gene expression, p130 (and p107, but not Rb) can also function as a Cdk inhibitor [132-135]. Thus, the ability of the virus to downregulate G1 cyclin/Cdk activity through the action of the p130 protein (and not p130's effects on E2F) may be critical for efficient HSV-1 replication. However, one must remember that compensation between the Rb family members may occur in null MEFs [136]. So firm conclusions about the necessity of the individual pocket proteins for HSV-1 replication await independent confirmation.

A notable corollary to these results is that while the Rb proteins remain unphosphorylated in HSV-infected cells, the activity of kinases responsible for their phosphorylation, the Cdks, appears to be critical for HSV-1 replication [137]. Cdk activity is required for the efficient expression of viral genes [138]. Although the mechanism is not completely understood, transcriptional Cdks may contribute to HSV infection by regulating cellular RNA Polymerase II function [139] and/or enhancing the ability of the viral ICP0 protein to activate transcription [140]. Interestingly, the viral UL42 protein may serve to target the Cdks to their substrates in some of these putative phosphorylation events [141], either instead of, or in addition to, cellular cyclins.

Varicella Zoster Virus

Cells infected with VZV do not progress into the S phase, but appear to arrest at the G1/S border [142]. Rb and p107

are not phosphorylated in VZV infected cells [142], similar to the results described above for HSV-1. The status of p130 in VZV infected cells has not been examined. However, unlike HSV-1, VZV infection induces the expression of cyclins D3, A, and B1 (but not cyclin E), and elevated Cdk2 and Cdk4 activity is observed [142,143]. Interestingly, this Cdk activity was observed in the presence of the Cki proteins p21 and p27. It is still unclear how these kinases remain active but do not phosphorylate Rb, a normal activity of these cyclin/Cdk complexes.

Small molecule Cdk inhibitors also inhibit VZV infection [144,145]. The broad spectrum Cdk inhibitor roscovitine reduces viral gene expression, viral DNA replication, and infectious virion formation [144], and a selective inhibitor of Cdk1 prevents the phosphorylation of the IE62 protein (immediate early protein of 62 kDa), a viral transcription factor [145]. Thus in a manner similar to HSV-1, Cdks seem to regulate viral gene expression, but not Rb protein phosphorylation, in VZV infected cells.

Alphaherpesvirus summary

While Cdk activity clearly contributes to alphaherpesvirus infections, the Rb family proteins do not appear to be critical substrates of these kinases in cells infected with HSV-1, HSV-2, or VZV. These observations lead to two subsequent questions: why doesn't active Rb inhibit the replication of these DNA viruses, and what are the significant substrates of the active Cdks in alphaherpesvirus infected cells?

A potential answer to the first question is revealed upon a genomic comparison of the different human herpesviruses. While the cadre of DNA synthesis functions encoded by the three different classes of herpesviruses is similar, the alpha- and gammaherpesviruses encode considerably more nucleotide biosynthetic enzymes than the betaherpesviruses (Fig. 2). Thus, alphaherpesviruses (and perhaps gammaherpesviruses) may be less dependent on cellular E2F-responsive genes for viral DNA replication than the betaherpesviruses (see below) and therefore may not need to target Rb family members for inactivation (Fig. 1).

Candidates for important Cdk substrates in alphaherpesvirus infected cells include viral proteins and cellular RNA polymerase II. Determining whether the "cell cycle" Cdks (Cdk1, 2, 4, 6), the "transcription" Cdks (Cdk7, 9), or both are relevant targets for the broad spectrum Cdk inhibitors that decrease alphaherpesvirus replication may help define the critical targets of the kinases in infected cells. Also, determining how the Cdks recognize their targets could also be informative. Are cyclin/Cdk complexes relocalized during infection? Do viral proteins supplant cellular cyclins and re-direct Cdks to different substrates?

Answers to these questions may help to resolve how Rb family members remain in their hypophosphorylated forms during alphaherpesvirus lytic infections even though some Cdks are active. Finally, the roles of Rb proteins and Cdks during latency of these viruses should be examined.

Betaherpesviruses

The human betaherpesviruses [111,146-150] include Human Cytomegalovirus (HCMV, HHV-5), Human Herpesvirus 6A and 6B (HHV-6) and Human Herpesvirus 7 (HHV-7). These viruses are extremely common, with more than 90% of the population infected [147,149,151-153]. HCMV infections are mostly asymptomatic in healthy adults, but can cause severe disseminated disease in immunocompromised and immunosuppressed people [151]. HCMV is the leading infectious cause of birth defects, contributes to graft loss in transplant patients, is associated with atherosclerosis and restenosis, and becomes the major target of host cell-mediated immunity in older people, leading to immunosenescence [154]. A causative role in human malignancies has not been demonstrated, but HCMV is being evaluated as a cofactor for certain cancers, most notably glioblastoma. HHV-6 and HHV-7 are causative agents of exanthem subitum ("sudden rash"), a mostly benign disease in young children characterized by a fever and subsequent red rash (roseola) [150]. Collectively HHV-6 and HHV-7 are termed the Roseolaviruses. Like HCMV, reactivation of latent HHV-6 and HHV-7 infections in immunocompromised or immunosuppressed patients can be problematic. Betaherpesviruses are lymphotropic, but the true latent reservoirs of these viruses remain undefined. Lytic replication cycles are slow and can occur in multiple cell types *in vivo*, but are generally restricted to non-transformed human cells in culture. Persistent replication in salivary glands may be important for the natural transmission of these viruses to new hosts.

Human cytomegalovirus

Infection of quiescent fibroblasts with HCMV results in their reentry into the cell cycle, progression through the G1 phase, and an eventual arrest at the G1/S border [155-161]. Infection of cycling cells also induces a G1/S arrest [160-162]. In G0 arrested cells, HCMV infection causes elevated levels of Rb which accumulate solely in the hyperphosphorylated form [156]. An examination of the very early stages of HCMV infection of quiescent fibroblasts indicated that hypophosphorylated Rb is first degraded, and then phosphorylated [163]. Both activities appear to be required for the absence of hypophosphorylated Rb, and the accumulation of hyperphosphorylated Rb during HCMV infection. Multiple HCMV proteins have been presented as candidate regulators of the Rb family proteins by degradation, phosphorylation or sim-

ple binding and inactivation. Furthermore, it is possible that HCMV can directly activate E2F-mediated gene expression independently of Rb. The individual viral proteins that modulate Rb, and the roles that they play in viral infection are discussed below.

Rb degradation in HCMV infected cells

The HCMV pp71 protein (a phospho-protein of 71 kDa) is a prominent component of the viral tegument [107,164] that binds to Rb and induces its degradation in a proteasome-dependent, ubiquitin-independent manner [165,166]. pp71 also binds and degrades p107 and p130 [166]. An LxCxD sequence in pp71 is required for Rb family degradation and for the ability of ectopically expressed pp71 to drive quiescent cells into the S phase of the cell cycle, as a mutant pp71 with an LxGxD motif (called C219G) failed to function in these assays [166]. pp71 can also accelerate progression through the G1 phase of the cell cycle by an unknown mechanism that is likely Rb-independent, because the LxCxD motif is not required for this activity [167]. Interestingly, pp71-mediated cell cycle stimulation does not induce apoptosis and pp71 is unable to cooperate with cellular or viral oncogenes to transform primary rodent cells *in vitro* [166,168], unusual properties for an Rb inactivating protein.

The early work on pp71 degradation of Rb was performed outside of the context of an HCMV infection, and in cell types non-permissive for HCMV infection. More recent experiments have addressed the role for this function of pp71 in HCMV infected, fully permissive fibroblasts *in vitro*. A virus expressing only the C219G mutant from pp71 replicates as well as wild-type HCMV [169], indicating that at least in fibroblasts *in vitro*, Rb degradation by pp71 is not required for lytic replication, perhaps due to the multiple, redundant mechanisms HCMV uses to modulate the Rb-E2F pathway (see below). However, infection with this C219G mutant virus was used to demonstrate that pp71 is required for the degradation of hypophosphorylated Rb at very early times after HCMV infection [163]. pp71 is introduced into cells immediately upon infection and mediates the transient drop in the steady state levels of Rb that can be seen as soon as 2 hours after infection [163].

Although Rb degradation by tegument-delivered pp71 may not be required for lytic replication, degradation of another pp71 substrate, the Daxx protein, greatly enhances lytic replication [169-173]. Daxx is a transcriptional co-repressor that silences the HCMV major immediate early promoter (MIEP) [172,174,175]. The MIEP controls the expression of the viral IE proteins that, when expressed, commit the virus to the lytic replication cycle. By degrading Daxx, pp71 relieves this repression, facilitating IE gene expression and lytic replication. Because IE

proteins, and an early protein (UL97) whose expression is activated by them, also regulate Rb (see below), pp71 appears to have both direct and indirect effects on the Rb-E2F pathway. Daxx degradation by pp71 is especially important during low multiplicity infections [169,170], and maintaining Daxx-mediated repression of the MIEP by preventing pp71 from degrading Daxx may contribute to the IE gene silencing that is observed when latent infections are established [176].

Interestingly, the substrates of pp71 (both Rb and Daxx) although initially degraded, re-accumulate at later times after infection [163,164,170,177]. It is presently unclear whether this is a result of an inhibition of pp71-mediated degradation, enhanced production of these pp71 targets, or both. Also unclear is the significance (and mechanism) of the uncommon ubiquitin-independent mode of proteasomal degradation mediated by pp71 [165,177]. Because pp71 can induce the degradation of its substrates when expressed alone in cells [165,170,177], no other viral proteins are required. However it is not known if cellular proteins (other than the proteasome) are required for pp71-mediated protein degradation. The importance of pp71-induced protein degradation to HCMV lytic infection and the uncommon method of that degradation make this an attractive target for the development of an inhibitory drug that may have potent antiviral activity but limited toxicity to uninfected cells.

Rb phosphorylation in HCMV infected cells

The Rb protein becomes hyper-phosphorylated as soon as 4 hours after HCMV infection of quiescent (G0) cells [156]. HCMV infection activates cyclin E- and cyclin B-dependent kinase activity [156,159] (but not cyclin D- or cyclin A-dependent kinase activity), and cyclin E/Cdk2 complexes are known to phosphorylate Rb. Thus it was surprising to find that small molecule inhibitors of the Cdk2 used at levels that completely inhibited serum induced Rb phosphorylation had no effect on Rb phosphorylation in HCMV infected cells [163]. Studies with additional inhibitors demonstrated that the activity of the HCMV UL97 protein kinase was absolutely required for Rb phosphorylation in HCMV infected cells [163]. UL97 directly phosphorylates Rb *in vitro*, and specifically targets multiple residues that, when phosphorylated, disrupt Rb-E2F and Rb/HDAC complexes, rendering Rb inactive [163]. Ectopic expression of UL97 drives quiescent cells into the S phase of the cell cycle [163], and recombinant HCMVs that express either no [178] or a catalytically inactive form of UL97 [163,179] fail to induce Rb phosphorylation [163,180]. Thus the HCMV protein kinase UL97 is necessary and sufficient for the phosphorylation and inactivation of the Rb protein.

UL97 is a serine-threonine kinase [179] that augments, but is not absolutely required for HCMV lytic replication

in fibroblasts *in vitro* [178]. UL97 null viruses have a substantial (100-fold) [178] growth defect that is partially (10-fold) rescued by propagation on dividing cells [178]. Deletion of the UL97 gene or inhibition of UL97 kinase activity results in a 5- to 20-fold decrease in viral DNA replication [181]. One might predict that this defect may be due to lower levels of certain E2F-responsive genes involved in nucleotide biosynthesis in these cells, and experiments to address this hypothesis are currently underway in our laboratory. Virion assembly and egress are also adversely affected by the absence of UL97 kinase activity [181], perhaps resulting from defects either in tegument protein phosphorylation/localization [182,183], or nuclear lamina breakdown [184]. UL97 is also a key protagonist for the small arsenal of drugs available to treat HCMV infections. UL97 is required to phosphorylate and thus activate the ganciclovir family of antitherpesvirus drugs [185,186], and UL97 itself is the target of maribavir [187-189], a compound currently in phase III clinical trials for treatment of HCMV-associated disease. The mutually exclusive and antagonistic actions of these drugs [190] unfortunately prevent their simultaneous use in a combination therapy regimen.

UL97 phosphorylates Rb and drives cell cycle progression, functions which are carried out in uninfected cells by the Cdk2s. In fact, UL97 can be described as a functional ortholog of cellular Cdk2 because it rescues the cell cycle defect in yeast cells lacking Cdk2 activity [163]. Interestingly, UL97 appears to be an unregulated Cdk2 ortholog that is not subject to the normal control mechanisms that can be instituted to restrict cellular Cdk2 activity, such as the requirement for activation by CAK-mediated phosphorylation and cyclin binding, and the inhibition by a specific tyrosine phosphorylation or binding by the Cks2 [163].

Without the need for cyclin binding, we wondered how UL97 was able to target Rb. Cellular cyclins have two sequence elements that could direct Cdk2s to phosphorylate Rb. The D-type cyclins have LxCxE motifs that bind in the Rb pocket domain, and all cyclins have a hydrophobic patch that interacts with RxL motifs in C terminus of the Rb protein. Interestingly, we found that UL97 contains both motifs. In fact, UL97 has three LxCxE motifs, although disruption of any individual site has minimal effects on Rb phosphorylation [180]. We are currently generating LxCxE and hydrophobic patch mutants to determine if these sequences direct UL97 to phosphorylate Rb.

Roles for viral IE proteins in modulating the Rb-E2F pathway

The HCMV Immediate Early-1 and -2 proteins (IE1 and IE2) are promiscuous transcription factors. IE1 is required for replication at low multiplicities of infection [191,192], and stimulates cell cycle progression, but only in p53-null

or p21-null cells [193,194]. IE1, through its first 85 amino acids, interacts with the Rb family member p107 [195,196], but not with Rb [197], and relieves p107-mediated, but not Rb-mediated repression of an E2F-responsive reporter [195]. A single report a decade ago proposed that IE1 was a kinase that phosphorylated p107 and p130 (but not Rb) *in vitro* [198]. *In vivo* phosphorylation was not examined. That study identified a 23 amino acid region within IE1 containing homology to the ATP-binding sites of over 500 other kinases [198]. However, our computer searches have not revealed this homology. Furthermore, we have clearly shown that Rb is not phosphorylated in HCMV infected cells that express IE1 but do not express UL97, indicating that IE1 likely does not play a direct role in Rb phosphorylation during HCMV infection [163]. More experiments are needed to determine if IE1 and/or UL97 is required for p107 and/or p130 phosphorylation in HCMV infected cells.

IE2 is absolutely required for lytic infection [199], and has been reported to bind Rb both *in vitro* and *in vivo* [200-202]. Amino acids 290-390 of IE2 are required for Rb binding [201], and this binding is abrogated by cyclin A-induced phosphorylation of Rb [200]. This binding could contribute to Rb inactivation in combination with prior pp71-mediated Rb degradation and subsequent UL97-mediated Rb phosphorylation. Additionally, IE2 has been shown to bind directly to the cyclin E promoter [203], and IE2 mutants lacking the first 194 amino acids (but retaining the putative Rb-binding region) fail to activate transcription and are unable to stimulate the cell cycle [204]. Thus, IE2 modulation of the Rb-E2F pathway may actually bypass Rb and act directly on E2F-responsive promoters.

The IE1 and IE2 transcripts share exons 1-3 and thus are identical through their first 85 amino acids. Their subsequent sequences are different because of alternative splicing of the gene, with IE1 using exon 4 and IE2 using exon 5. Interestingly, a viral mutant lacking exon 3 (IE1 and IE2 amino acids 30-77) is viable, but has a severe growth defect, and importantly fails to fully activate the expression of cyclin E [205], an E2F-responsive gene. The defect in cyclin E gene activation was not rescued by ectopic expression of IE1, indicating that IE2 (and not IE1) is required for full activation of cyclin E in HCMV infected cells [205]. The expression of UL97 in cells infected with this virus has not yet been examined and thus this mutant virus may be defective in E2F-mediated gene expression for multiple reasons. Interestingly, IE2 also arrests cell cycle progression in early S phase by an unknown mechanism [206,207].

Role of Rb inactivation during HCMV replication and pathogenesis
During HCMV infection, Rb is inactivated and E2F-responsive genes are highly expressed [208]. Hypophos-

phorylated Rb is not found in HCMV-infected cells because it is first degraded by pp71 and then phosphorylated by UL97, and both of these phenomena should induce the expression of E2F-responsive genes. Expression of E2F-responsive genes also appears to be directly activated by IE2, independently of the Rb protein. Although IE1 has been shown to stimulate the cell cycle when exogenously over expressed (in p53 or p21 mutant cells), it does not appear to have a significant effect on cyclin E expression in the context of an HCMV infection of wild-type cells. It appears that HCMV encodes partially redundant mechanisms to ensure efficient Rb inactivation and robust E2F-responsive gene expression. The role of Rb inactivation during HCMV replication and pathogenesis is not yet known, but could be required for the accumulation of nucleotide biosynthetic and other enzymes involved in DNA replication that the virus could then usurp for the replication of its own genome. The roles of p107 and p130 during HCMV infection have not been extensively studied, although a novel p130-containing complex likely regulates cyclin E expression during HCMV infection [209].

Human herpesvirus 6 and 7

We could find only one report of the effects of HHV-7 on cell cycle progression. In that study [210], primary or immortalized T cells infected at a low MOI (0.1 pfu/cell) were observed to display elevated DNA contents after ten days of infection similar to the 4n levels of DNA observed in cells in the G2 or M phase of the cell cycle. While the authors concluded that HHV-7 institutes a G2/M arrest, it is unclear if the newly synthesized DNA observed in these cells is viral or cellular. In fact, elevated levels of cyclin B were observed in cells with DNA contents corresponding to the G1, S, and G2/M phases of the cell cycle [210]. Levels of Cdk1 were also increased following HHV-7 infection [210]. No other cell cycle markers were analyzed. The results could be consistent with the authors' conclusion (a G2/M arrest), or may mimic the results seen with HCMV, where cells are arrested at the G1/S border but also express cyclin B, and where the DNA content increase in infected cells is attributed to viral, but not cellular DNA replication [156,159].

More work has examined the effects of HHV-6 infection on cell growth. T cells [211] or epithelial cells [212] infected with HHV-6B, and glial precursor cells infected with either HHV-6A or HHV-6B [213], stop dividing, rapidly cease synthesizing cellular DNA, and arrest with a G1/S (2n) DNA content. The G1/S arrest was clearly shown in glial precursor cells [213] by using a previously described method [214,215] in which the microtubule depolymerizing agent nocodazole is used to trap cycling cells in the G2/M phase, allowing for unambiguous quantitation of cells trapped in G1. While the levels of the p53 tumor suppressor are elevated in HHV-6 infected cells

[211,212,216] (as they are during HCMV infection), p21 levels are not elevated [212,217], and the G1/S arrest appears to be p53-independent [212]. Cord blood mononuclear cells infected with HHV-6A (and to a lesser extent HHV-6B) showed significantly elevated levels of p53 and cyclin B, and a modest induction of cyclins A and E [217]. Similar to the HHV-7 study [210], the conclusion of a G2/M arrest based on the late accumulation of cells with a 4n DNA content is complicated by the inability to distinguish viral and cellular DNA by flow cytometry.

No studies that analyzed the ability of HHV-6 or HHV-7 to stimulate cell cycle progression or to modulate the Rb-E2F pathway at the molecular level could be found. Therefore, we compared the amino acid sequences of the HCMV proteins that modulate the Rb-E2F pathway (pp71, IE2, and UL97) to their HHV-6 and HHV-7 orthologs (U54, U86, and U69, respectively) in an attempt to predict how HHV-6 and HHV-7 may regulate progression through the G1 phase of the cell cycle. The pp71 orthologous U54 genes had no LxCxE motifs, indicating that if it does modulate Rb, it does so in a manner distinct from pp71. The IE2 orthologous U86 genes were found to be around 20% identical and 65% similar to IE2 within the regions of IE2 implicated in cell cycle induction (residues 1–194) and Rb binding (residues 290–390). Because small functional motifs within these regions have not been mapped, it is difficult to know whether this level of homology can indicate that conserved or divergent activities may be mediated by these protein domains. The UL97 orthologous U69 genes lacked a discernable hydrophobic patch, and contained only a single LxCxE motif that aligned with the first LxCxE motif in UL97. Interestingly, these proteins robustly phosphorylate Rb in transfected Saos-2 cells (Chad Kuny and Rob Kalejta, manuscript in preparation). Thus it seems likely that HHV-6 and -7 at least phosphorylate Rb through the action of their virally encoded protein kinase. Whether or not these viruses encode the multiple redundant functions of HCMV that modulate this pathway remains to be determined.

Betaherpesvirus summary

Although cellular Cdks don't appear to play a role in the phosphorylation of Rb during HCMV infection, their activity is required for efficient viral replication as evidenced by reduced viral yields in the presence of a Cdk inhibitor such as roscovitine or a dominant-negative Cdk2 [218–221]. Thus, analogous to the alphaherpesviruses, Cdks play a significant role in viral replication despite their inability to phosphorylate Rb, and the relevant cellular and viral targets of the Cdks in HCMV-infected cells have yet to be identified. Although not a result of Cdk activity, the Rb protein is efficiently inactivated in HCMV infected cells, and E2F responsive genes

are highly expressed. The conspicuous absence of almost all of the nucleotide biosynthetic enzymes encoded by the alpha- and gammaherpesviruses (Fig. 2) indicates the possibility that the beta herpesviruses are hyper-dependent on cellular enzymology for nucleotide synthesis and metabolism (see below).

In terms of pathogenesis, numerous studies have found HCMV, HHV-6, and HHV-7 genomes or proteins in cancerous cells or tissues [147,148,222]. However, the ubiquitous nature of these viruses means that such association studies need to be interpreted with caution. Certainly HCMV encodes multiple proteins that stimulate the cell cycle (Fig. 1) and that, theoretically, could have oncogenic potential. Sequence analysis and preliminary data indicate that at least one of the HHV-6 and HHV-7 orthologs of those proteins, the UL97 orthologous U69 protein kinases, are likely to have similar effects. In addition, HCMV encodes numerous anti-apoptotic proteins [223] and infection has been shown to prevent the death of some cancerous cells [224]. If any of these pro-proliferative or anti-apoptotic proteins were to be driving forces behind oncogenesis, their continued expression in tumors would appear to be essential to maintain the transformed phenotype. In addition, some HCMV proteins are mutagenic [225] and thus may cause genomic instability leading to cancer through a "hit and run" mechanism. Thus, multiple functions of these viruses could contribute to oncogenesis.

However, infection with beta herpesviruses does not transform cells *in vitro*. Furthermore, HCMV encodes many proteins that can arrest cell cycle progression, such as UL69 [226,227], IE2 [206,207] and UL117 (Yu, D. and Qian, Z. 2008 International Herpesvirus Workshop abstract). Furthermore, the HHV-6A U94 protein has been reported to suppress H ras-mediated transformation [228]. Many questions remain as to whether beta herpesviruses are opportunistic bystanders or propelling forces when they are found in human tumor samples, and if, in analogy to the papillomaviruses, there are "high risk" and "low risk" beta herpesviruses. The HCMV strains studied *in vitro* were isolated from patients with various manifestations of disease (e.g. tonsillitis, retinitis, congenital infections, transplant patients), but none that we know of were isolated from cancer patients. Comparisons of these strains to ones isolated from patients with potentially HCMV associated cancers may or may not reveal differences in the viral cell cycle regulatory proteins between strains. Furthermore, because most of the proteins with oncogenic potential are expressed only during lytic replication, it is unlikely that latently infected cells are transformed (as is the case for the gammaherpesviruses; see below), perhaps indicating that abortive or persistent infections may be linked to oncogenesis. To complement

the epidemiological studies, translational approaches such as *in vitro* molecular analysis of betaherpesvirus infected cells isolated from human tumors could begin to answer the many confounding questions related to the potential direct role of these viruses in human cancers.

Gammaherpesviruses

The human gammaherpesviruses [229-237] include Epstein Barr Virus (EBV, HHV-4) and Kaposi's Sarcoma Associated Herpesvirus (KSHV, HHV-8). EBV is common within the population (over 90% are EBV positive), infects B cells and epithelial cells, is transmitted orally, and causes infectious mononucleosis [229]. EBV is also associated with cancers, including B cell tumors such as Burkitt's lymphoma and Hodgkin's lymphoma, and epithelial tumors such as nasopharyngeal carcinoma [229,230,238]. In these cancers, EBV is maintained in a latent state. While most pathologies related to EBV are caused by latent infection, lytic EBV is associated with the proliferative disorder oral hairy leukoplakia in immunocompromised patients [229]. KSHV is uncommon in the general population (less than 7%, but some geographical areas have infection rates as high as 60%) infects B cells and endothelial cells, and is transmitted sexually. A latent KSHV infection is associated with Kaposi's Sarcoma, Primary Effusion Lymphoma (PEL), and a subset of Multicentric Castlemans Disease (MCD) [231,239]. The gammaherpesviruses are characterized by their tropism for lymphocytes, the association of their latent infections with human cancers, and the difficulty in modeling their lytic replication cycles *in vitro* [231].

Epstein Barr virus

Lymphoblastoid cell lines (LCLs) develop when primary B-lymphocytes are infected *in vitro* with EBV [232,233]. LCLs are immortalized and transformed, so they proliferate and divide. Not surprisingly, they were found to have higher levels of Cdks and G1 cyclins compared to primary B-lymphocytes, and to harbor phosphorylated forms of Rb and p107 [240,241]. EBV infection in LCLs is latent. The viral genome is maintained as a circular episome and is replicated mainly by cellular proteins, although EBNA-1 (Epstein-Barr Nuclear Antigen - 1) is required for its replication and faithful partitioning during cell division [232,233,242]. In LCLs, EBNA-1, EBNA-2, EBNA-3a, EBNA-3c, EBNA-5 (EBNA-LP) and LMP1 (Latent Membrane Protein - 1) cooperate to induce and maintain the transformed phenotype [232,233]. A number of these proteins (and a few others) have been reported to affect the Rb-E2F pathway and are discussed below.

EBNA-5 does not have an LxCxE motif or hydrophobic patch, but has been reported to bind Rb in GST pull down experiments [243]. However, this protein was unable to counteract the repressive effects of Rb or p107 on a

reporter construct under the control of a Gal4-E2F-1 fusion protein [244], so the relevance of Rb binding is unknown. In cooperation with EBNA-2, EBNA-5 can activate the expression of cyclin D2 when overexpressed in resting B cells stimulated with the viral gp350 envelope protein [245]. The ability of other EBV latent proteins to induce cyclin D2 expression under these conditions was not analyzed. More direct assays are required to determine if EBNA-5 can regulate the Rb-E2F pathway, and what role such putative modulation may have in the creation of LCLs upon EBV infection of primary B cells.

LMP-1 has also been reported to modestly induce cyclin D2 expression, perhaps indirectly through the induction of the cMyc and AP1 transcription factors, and to maintain Rb in a hyperphosphorylated state in B cells treated with TGF- β [246,247]. Other EBV latent proteins were not analyzed for this function. Additional ways that LMP-1 may contribute to inducing E2F-mediated gene expression and cell cycle progression are by down regulating the expression of the Cki p16 [248] through inducing the nuclear export of the Ets2 transcription factor that induces p16 expression [249], and by causing the nuclear export of E2F-4 and -5 (the "inhibitor E2Fs") perhaps through disrupting their ability to bind Rb [249]. Because D-type cyclin expression is induced by growth factor signaling, it is straightforward to imagine how a membrane protein such as LMP-1 might activate cyclin D2 expression through activation of the signaling cascade involved in normal induction of cyclin D expression. It is more difficult to envision how such a protein may specifically regulate the nuclear export and complex formation of certain transcription factors, unless this is an indirect effect.

The EBNA-3C protein has also been implicated in modulating the Rb pathway. Although it lacks an LxCxE motif or a discernable hydrophobic patch, early work reported an interaction between *in vitro* translated and labeled EBNA-3C and GST-Rb [250]. In this same study, EBNA-3C also cooperated with activated ras to transform rodent cells. This transformation was insensitive to inhibition by over expression of p16 [250], leading the authors to speculate that inactivation of Rb, perhaps by inhibition of p16 or stimulation of cyclin D-dependent kinase activity was the mechanism through which EBNA-3C contributed to cellular transformation. A subsequent report showed that EBNA-3C was required for the continued proliferation of LCLs and for keeping the levels of both the p16 protein and transcript low [251]. This compelling study proposed that EBNA-3C may repress the transcription of p16, but provided no mechanism, and no indication that repression of p16 was necessary or sufficient for EBNA-3C induced proliferation of LCLs. A recent report proposed a p16-independent way in which EBNA-3C may modulate the Rb pathway. By translocating the mitochondrial pro-

tein MRS18-2 into the nucleus, EBNA-3C has been reported to facilitate MRS18-2 binding to Rb and disruption of Rb-E2F complexes [252]. The mechanism by which EBNA-3C could shuttle MRS18-2 to the nucleus remains unexplored.

Other means through which EBNA-3C may modulate the Rb pathway have also been proposed. EBNA-3C may increase cyclin A-dependent kinase activity by associating with cyclin A, disrupting its binding to the Cki p27, and leading to p27 degradation [253,254]. While the C terminus of EBNA-3C was required to render cyclin A insensitive to p27 [253], the same group subsequently found an N-terminal region of EBNA-3C (amino acids 130 to 159) bound more strongly to cyclin A (and bound to cyclins D1 and E), and inhibited cyclin A-dependent kinase activity [254]. Curiously, this same region (amino acids 140 to 149) was also implicated by this group in the EBNA-3C-mediated degradation of p27 [255] and Rb, but not p107 or p130, by recruitment of the Skp2 ubiquitin ligase complex [256]. It is unclear how this observation relates to the ability of hypophosphorylated Rb in uninfected cells to induce the degradation of Skp2 and thus result in cell cycle arrest by preventing Skp2-mediated degradation of p27 [257,258]. Because this small region of EBNA-3C may have multiple and possibly important effects on cell cycle progression, it is now critical to examine the role of this region of EBNA-3C in the context of an EBV infection.

The EBV genes expressed in LCLs are referred to as the latency III phenotype and can be expressed by EBV-positive cancers in immunocompromised patients [232,233]. Interestingly, in most natural latent EBV infections that lead to cancers in immunocompetent hosts, fewer genes are expressed. The only gene product implicated in Rb regulation that is consistently expressed in EBV positive tumors is LMP-1 [232,233]. It is likely that the extra latency III genes are initially expressed *in vivo* in all EBV transformed cells. However, the growth advantage they provide may be quickly outweighed by a propensity to permit immune detection and clearance, and thus are only consistently found in EBV transformed cells *in vitro* or in immunocompromised hosts. Therefore, in immune competent hosts, it is likely that an accumulation of additional cellular mutations (such as translocations that activate c-Myc expression) provide the growth or survival advantages required for transformation in the absence of latency III proteins. The required accumulation of these mutations along with immune surveillance may explain the low frequency with which natural infections lead to cancer as compared to the much higher *in vitro* transformation efficiency of EBV.

When latent EBV is induced to reactivate a productive lytic infection, the infected cells rapidly cease dividing and syn-

thesizing cellular DNA, and arrest at the G1/S border with hyperphosphorylated Rb and elevated levels of cyclins E and A [259,260]. The two viral proteins that drive lytic reactivation, Z and R, may also play significant roles in these cell cycle effects. When expressed alone, the EBV Z protein has been shown to induce the expression of certain S phase genes, but also to arrest cell cycle progression in both the G1 and G2 phases [261-263]. These effects may be cell type specific. Thus Z appears to have similar activities to the HCMV IE2 protein that induces and then subsequently arrests cell cycle progression. The ability of Z to directly bind to Rb has not been shown. The EBV R protein does not have an LxCxE motif or a discernable hydrophobic patch, but still binds to Rb [264] and stimulates cell cycle progression [265]. In cells overexpressing R, low levels of Rb, p107 and p130 were observed [265] but the ability of R to degrade the Rb proteins was not examined. These cells also expressed high levels of E2F-1, and eventually died by apoptosis. In addition to the cellular E2F-responsive genes that likely contribute to viral DNA replication during EBV lytic replication, the viral DNA polymerase also appears to be an E2F-responsive gene [266].

Small molecule Cdk inhibitors were able to inhibit EBV lytic replication and viral gene expression [267]. In these inhibitor treated cells, Rb was found to be hypophosphorylated, perhaps indicating that cellular Cdks are responsible for phosphorylating Rb in lytically induced EBV infected cells. However, we have shown that the HCMV kinase UL97, and not the Cdks, phosphorylates Rb during HCMV lytic replication. Furthermore, our preliminary experiments indicate that the EBV ortholog of UL97, the BGLF4 protein, can also phosphorylate Rb when transfected into Saos-2 cells (Chad Kuny and Rob Kalejta, manuscript in preparation). Thus the small molecule Cdk inhibitors may prevent the expression of BGLF4 during EBV lytic reactivation, with BGLF4 (and not the Cdks) being directly responsible for the phosphorylation of Rb. More work is required to determine which kinase or kinases phosphorylate Rb during lytic EBV infection, and if the relevant targets of the small molecule Cdk inhibitors that prevent EBV lytic infection are the "cell cycle" Cdks or the "transcription" Cdks.

Kaposi's sarcoma associated herpesvirus

Latent KSHV infections are studied *in vitro* either in cell lines established from PELs, or by infection of endothelial cells to create "spindle cells", similar to those observed in natural KS lesions. Cells latently infected with KSHV consistently express three proteins; LANA (latency associated nuclear antigen; ORF73), v-cyclin (viral cyclin; k-cyclin; ORF72), and V-FLIP (viral FLICE inhibitory protein; ORF71; K13) [268].

Although it lacks an LxCxE motif or a hydrophobic patch, LANA binds to and inactivates Rb, and cooperates with H-ras to transform rodent cells [269]. Proliferative diseases were also observed in transgenic mice expressing LANA from its endogenous promoter [270]. In addition to direct inactivation, LANA has also been reported to inactivate Rb through indirect mechanisms. By sequestering the GSK3 β kinase in the nucleus, LANA expression leads to the stabilization of β -catenin, which in turn leads to the induction of cyclin D1 expression and the subsequent stimulation of G0 cells into the cell cycle [271]. LANA, and to a lesser extent v-cyclin, increases the levels of Id-1, perhaps by a post-transcriptional mechanism [272]. The Id proteins are naturally occurring dominant negative inhibitors of basic helix-loop-helix DNA binding transcription factors that are implicated in many processes such as the inhibition of differentiation and the stimulation of cell cycle progression [273]. However, because Id protein levels increase as cells progress through the cell cycle, it is unclear if LANA effects on Id-1 are direct or indirect, that is if they induce, or are induced by, cell cycle progression. Regardless of the mechanism(s), LANA expression has been clearly shown to activate a subset of E2F-responsive genes [274] presumably through Rb inactivation, because reporter assays and *in vitro* binding studies indicate that LANA is likely unable to inactivate either p107 or p130.

KSHV also encodes an ortholog of cellular cyclin D (v-cyclin) that is expressed during both lytic replication and latency [268,275-280] and phosphorylates Rb [276,281-283]. v-cyclin lacks the LxCxE motifs found in the D-type cyclins, but does have a hydrophobic patch that is highly conserved among herpesvirus-encoded cyclins [284]. It is not known whether the hydrophobic patch is required for Rb phosphorylation. Although it can bind to Cdk2, 4, 5, and 9, v-cyclin preferentially pairs with Cdk6 [276,281,282]. v-cyclin/Cdk6 complexes have an extended substrate range (compared to cyclin D/Cdk6) that includes targets of cyclin E and cyclin A [276,277,281,285-289]. In addition, v-cyclin is immune to a number of cellular control mechanisms that can attenuate the activity of cellular cyclin/Cdk complexes [290]. For example, v-cyclin lacks a destruction box so it is more stable than cellular cyclins [291], it is immune from inhibition by the CkIs [285,286,292], accumulates in the nucleus [293], and supports Cdk6 kinase activity in the absence of CAK phosphorylation [293,294]. Outside the context of a KSHV infection, v-cyclin can cooperate to transform rodent cells in culture and promote lymphoma formation in transgenic mice [295]. Through the phosphorylation and stabilization of p53 v-cyclin causes a G1 cell cycle arrest [296], so cell cycle stimulation and transformation is more readily observed in p53 mutant cells. Cells from latent KSHV infections or associated cancers, however, are not growth inhibited, potentially through

the modulation of the p53 pathway by LANA [297]. Our preliminary evidence indicates that the KSHV-encoded kinase, the ORF36 protein, can also lead to Rb phosphorylation (Chad Kuny and Rob Kalejta, manuscript in preparation), indicating another potential mechanism for Rb inactivation during lytic replication.

Induction of lytic infection in PEL cell lines with TPA prevents them from entering the S phase [298] inducing an accumulation of cells with a G1 DNA content [299]. At least two lytic phase viral proteins seem to be involved in this G1 arrest. The K-bZIP protein (also known as RAP (replication associated protein) or K8), the structural and positional ortholog of the EBV Z protein, arrests cells in G1 [298,299]. Potential mechanisms for this arrest are the activation of p53 by direct binding [300], the stimulation of the transcription of the gene for the Cki p21 [298], and/or by directly binding and inhibiting cyclin E/A/Cdk2 complexes [299]. Interestingly, while K-bZip seems to share cell cycle functions with EBV Z, it is unable to induce lytic reactivation of latent KSHV infections [301]. This function seems to be confined to KSHV Rta, the ortholog of the EBV R protein [302,303]. The other lytic phase protein that has been shown to arrest PEL cells in G1, the viral G protein coupled receptor (v-GPCR, ORF74), likely does so through a p21-dependent mechanism [304]. This is intriguing in light of the fact that vGPCR is considered a transforming oncogene [305-309].

The viral cyclin is expressed during lytic infection as well [276,277]. Interestingly, the MGHV-68 cyclin is required for reactivation from latency [310]. Whether this is true or not for KSHV remains to be examined, but v-cyclin has been shown to phosphorylate different residues of p27 in latently and lytically infected cells [287], indicating that it may have important roles during both latency and lytic reactivation.

Gammaherpesvirus summary

In contrast with the alpha- and betaherpesviruses there is a clear association of gammaherpesviruses with proliferative disorders including a number of cancers. Furthermore, both EBV and KSHV appear to encode proteins that modulate the Rb-E2F pathway, either directly or indirectly (Fig. 1). However, what appears to be an unambiguous case of cause and effect may not be so straightforward. EBV certainly encodes transforming proteins required for the maintenance of LCLs created *in vitro*. However, most of those are not expressed in the majority of naturally arising EBV positive tumors. So while these proteins can transform cells, and EBV does cause cancer, the Rb-inactivating viral proteins that may help initiate transformation are not always required for the maintenance of the transformed state. Such a view fits well with the ability of EBV to potentially activate cellular E2F-responsive genes by

inactivating Rb (Fig. 1) while encoding a full complement of viral nucleotide biosynthetic enzymes (Fig. 2).

Similarly, while KSHV encodes Rb inactivating proteins (Fig. 1), a provocative study found that the Rb pathway could be reconstituted in KSHV infected PEL cells by expressing the Cki p16 [311]. The six PEL cell lines and four PEL tumor samples tested in this study were all found to be deficient for p16. Furthermore, when PEL cells were transduced with a recombinant adenovirus expressing p16, they arrested in the G1 phase of the cell cycle, and this arrest required the presence of the Rb protein [311]. Thus, even though PEL cells express LANA and v-cyclin, additional mutations (such as loss of p16) appear to be required to fully inactivate the Rb pathway. So even for the gammaherpesviruses, viral infection may not be sufficient for the complete inactivation of the Rb pathway that is required for carcinogenesis.

Interestingly, although Rb inactivating proteins such as v-cyclin are also expressed during lytic KSHV infection, this is unlikely to result in an increase in cellular E2F gene product accumulation. The KSHV-encoded SOX (shut-off and exonuclease; ORF37) protein mediates a broad shut-off of host gene expression [312-314] by causing the rapid turnover of more than 75% of host transcripts, while only 2% of host transcript levels increase in response to KSHV infection [315]. KSHV is likely immune to potentially negative effects of the downregulation of E2F responsive genes because it encodes the most nucleotide biosynthetic enzymes of any herpesvirus (Fig. 2).

Nucleotide biosynthetic enzymes (NBEs) and human herpesvirus infections

What effects do the many different ways that the human herpesviruses regulate the Rb protein (to inactivate it or keep it active) have in the context of viral infection? Rb controls the E2F transcription factors, and many E2F-responsive genes are involved in DNA replication, a process required by all human herpesviruses to replicate their own genomes. But all the human herpesviruses seem to encode most of the enzymology required for the actual process of DNA synthesis (Fig. 2). So if cellular helicases, primases, and polymerases aren't needed for viral genome replication, than what cellular factors, if any, are?

We hypothesize that the nucleotide biosynthetic enzymes (NBEs) represent the key Rb-E2F-regulated gene products of interest to the human herpesviruses. However, not all human herpesviruses appear to have an equal interest in these genes. As alluded to earlier, the alpha- and gammaherpesviruses encode between five and seven enzymes involved in nucleotide metabolism, whereas the betaherpesviruses encode only one activate enzyme (Fig. 2). Not surprisingly, by mining published [315-317] and unpub-

lished (Szpara and Enquist, personal communication) microarray studies, we found that a select set of cellular NBEs is elevated in HCMV infected cells, but not in HSV-1 or KSHV-infected cells (Fig. 3).

We selected a set of eleven cellular NBEs to analyze based on two criteria. First, we picked six cellular enzymes (TK1, RRM2, DUT, UNG, DHFR, TYMS) that have a virally encoded counterpart in at least one human herpesvirus. The second criteria was that the NBE was present on the arrays used to analyze changes in the expression patterns of cellular genes after infection with at least two of the three viruses (HSV-1, HCMV, and KSHV) for which we could access the primary data. There were five genes in this category (AK1, NME7, PPAT, CTIP5, PFAS). We analyzed the available microarray data to determine if the expression level of these genes changed after viral infection.

For KSHV, we found that during lytic infection, none (0/11) of the cellular NBEs analyzed were upregulated (Fig. 3). In fact, many were downregulated, likely due to the action of the viral SOX protein. KSHV can likely succeed without the need of cellular NBEs because it encodes the most viral NBEs of any human herpesvirus (Fig. 2). We could not find a microarray analysis of latently infected KSHV cells, but we would expect to see upregulated expression of the cellular NBEs because the viral NBEs are not expressed during latency. We could not access the data for the only EBV study we found in the literature [318].

We found a similar absence of upregulated cellular NBEs during lytic (1/11) infections of HSV-1 (Fig. 3). These results aren't surprising because HSV-1 encodes many viral NBEs that are expressed during lytic infection and encodes a nuclease (VHS) that can degrade cellular mRNAs. We did not analyze an HSV-1 latency microarray study. However, HSV-1 establishes latency in non-dividing neurons and thus doesn't need to replicate its genome to high levels and we suspect cellular NBE levels to be low in latently infected neurons. We could not find a microarray analysis of HSV-2 or VZV infected cells.

In contrast, HCMV infection upregulated more (4/11) of the cellular NBEs during lytic infection (Fig. 3). Both the promoter and enzymatic activity of one enzyme not upregulated in the microarray study, DHFR, was found to be increased in HCMV infected cells [319,320], and thus we could set the activated fraction even higher (5/11). Furthermore, the virus may not need the activity of two of the other enzymes because the UL97 protein that phosphorylates the nucleoside analog ganciclovir [185,186] may be able to phosphorylate other nucleosides, and thus may functionally replace TK1 and NME7. HCMV likely relies on cellular NBEs because it encodes only one catalytically active viral NBE (Fig. 2). This was surprising as HCMV has

the largest genome and the most genes of the human herpesviruses. We could not find microarray analysis of latent HCMV, HHV-6, or HHV-7 infections. What is not readily apparent is why or how the alpha- and gammaherpesviruses evolved to encode most of their own NBEs, while the betaherpesviruses seem to rely heavily on cellular enzymes. An intriguing hypothesis is that, by evolving multiple mechanisms to inactivate Rb, HCMV and perhaps betaherpesviruses in general may have eliminated their need to encode their own NBEs. The fact that betaherpesviruses each encode two catalytically inactive NBEs seems to lend credence to this theory. It would be interesting to determine if the expression of a full cadre of virus NBEs would obviate the need for some of the Rb inactivating proteins encoded by HCMV.

Conclusion

In addition to inducing the expression of cellular NBEs, there appear to be two other reasons why herpesviruses may modulate the Rb-E2F pathway. First, by manipulating this pathway, they can synchronize infected cells in a cell cycle position that favors the efficient replication of their DNA genomes, and by extension, their productive lytic replication cycles. Such synchronization appears to require both cell cycle stimulatory and arrest functions. This favorable cell cycle position can be thought of as the G1 phase for all the herpesvirus classes. G1 arrest presumably is beneficial because preventing the replication of the cellular genome allows for the unencumbered utilization of DNA precursors and replication enzymes for the sole production of viral genomes. While this hypothesis for the presumed benefit that cell cycle arrest seen during herpesvirus lytic infections provided for these viruses is commonly invoked (and makes perfect sense), there is surprisingly little direct evidence to support it. It is known that replication of HCMV, the largest and slowest human herpesvirus, is delayed and decreased by an IE2 point mutant that fails to arrest cell cycle progression [321]. However it is unclear if the inability to arrest the cell cycle is the only deficiency shown by this mutant allele of this essential HCMV protein. Furthermore, as herpesviruses such as HSV-1 and EBV have smaller genomes and replicate much faster, it might be expected that competition for nucleotides would have a quantitatively smaller effect on these viruses. More work is needed to determine why G1 appears to be a favored cell cycle position for herpesvirus lytic replication.

The second reason why herpesviruses may modulate the Rb-E2F pathway is to facilitate cell division and thus the expansion of the reservoir of latently infected cells. While lytic replication can rapidly increase the number of infected cells within a host, and the progeny virions that are created can mediate transmission to new hosts, lytically-infected cells are short-lived and subject to intrinsic,

innate, and adaptive immune defenses. Latency permits the long term persistence of infected cells that may be less visible to the immune system. If latently infected cells proliferate, or could be induced to proliferate, the reservoir of such cells could be expanded.

Thus, both lytic and latent infections of herpesviruses could conceivably benefit from modulation of the host cell cycle in general and the Rb-E2F pathway in particular. Below we summarize the data presented above for a representative member of each class of human herpesviruses (please see the companion figure, Fig. 4).

HSV-1, an alphaherpesvirus

Lytic replication

Cell cycle arrest functions are expressed (ICP0, ICP27), but no cell cycle stimulatory functions are expressed. Cells arrest in early G1 phase. The expression of many virally-encoded nucleotide biosynthetic enzymes (Fig. 2) likely renders HSV-1 relatively insensitive to changes in E2F-mediated gene expression.

Latency

Cell cycle effects in latently infected cells are unknown, but because latency is established in terminally differentiated sensory neurons and few viral genes are expressed, any effects would be expected to be minimum. The non-dividing nature of the latent reservoir appears to render HSV-1-independent of E2F-mediated gene expression during latency. Sensory neurons would seem to be a non-renewable resource, so reactivations would either need to be non-cytolytic, or very judiciously initiated. The expression of viral nucleotide biosynthetic enzymes during reactivation may allow for lytic replication without cell cycle induction, perhaps improving the chances for the survival of the latently infected neuron after lytic reactivation.

HCMV, a betaherpesvirus

Lytic replication

Cell cycle arrest (UL69, IE2, UL117) and stimulatory (pp71, IE1, IE2, UL97) functions are expressed. Infected cells are arrested at the G1/S border. The absence of many nucleotide biosynthetic enzymes encoded within the HCMV genome (Fig. 2) appears to make this virus dependent upon cellular E2F-responsive genes for efficient lytic replication.

Latency

Cell cycle effects during latent HCMV infections have not been examined. However, because few if any genes are expressed, and because transformation or immortalization of latently infected cells has not been demonstrated, it is unlikely that latency modulates the cell cycle. The absence of many HCMV-encoded nucleotide biosynthetic enzymes implies that reactivation requires cellular E2F-

mediated gene expression. Whether this leads to death of the reactivated cell is unclear. Because the undifferentiated cells that likely harbor latent virus would appear to be a renewable resource, the eventual death of the reactivating cell may have few consequences for the formation of life-long latency except for the need for continual reseeding of the latent reservoir.

EBV, a gammaherpesvirus

Lytic replication

Cell cycle arrest (Z) and stimulatory (R) functions are expressed. Infected cells arrest in late G1 phase. The expression of many EBV-encoded nucleotide biosynthetic enzymes (Fig. 2) likely renders EBV relatively insensitive to changes in E2F-mediated gene expression.

Latency

Cell cycle stimulatory functions are expressed in type I (LMP-1) and type III (LMP-1, EBNA-3C, EBNA-LP) latency, but cell cycle arrest functions are not. Latently-infected primary B cells are immortalized and transformed. They proliferate and divide, and so the virus must replicate and partition its genome to maintain the latent reservoir. The lack of expression of virally-encoded nucleotide biosynthetic enzymes during latency appears to make EBV reliant upon E2F-mediated cellular gene expression for viral DNA replication. Note that during latency, the amount of viral DNA replication (which is mediated by host cell polymerases) is negligible compared to the amount of host cell DNA being synthesized (in contrast to what happens during lytic infection). Because the B cells that harbor latent virus represent a renewable resource, the eventual death of the reactivating cell may have little effect on the ability of EBV to establish lifelong latency. Because latently infected cells can expand in number, a continual reseeding of the latent reservoir may not be necessary.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AJH and RFK contributed to the discussion and preparation of this manuscript.

Acknowledgements

We thank Leanne Olds for help with the illustrations, Shannon Kenney and Bill Sugden for helpful discussions and comments on the manuscript, and Moriah Szpara and Lynn Enquist for help with the microarray analysis, and for communicating data prior to publication. This work was supported by the Wisconsin Partnership Fund for a Healthy Future, the American Heart Association (0430186N), and the National Institutes of Health (R56-AI64703). AJH was supported by NIH training grants T32-CA009135 and T32-GM007215. RFK is a Burroughs Wellcome Fund Investigator in Pathogenesis.

References

1. Knudsen ES, Knudsen KE: **Tailoring to RB: tumour suppressor status and therapeutic response.** *Nat Rev Cancer* 2008, **8**:714-724.
2. Weinberg RA: **The retinoblastoma protein and cell cycle control.** *Cell* 1995, **81**:323-330.
3. Dick FA: **Structure-function analysis of the retinoblastoma tumor suppressor protein – is the whole a sum of its parts?** *Cell Div* 2007, **2**:26.
4. Burkhardt DL, Sage J: **Cellular mechanisms of tumour suppression by the retinoblastoma gene.** *Nat Rev Cancer* 2008, **8**:671-682.
5. Giacinti C, Giordano A: **RB and cell cycle progression.** *Oncogene* 2006, **25**:5220-5227.
6. Cobrinik D: **Pocket proteins and cell cycle control.** *Oncogene* 2005, **24**:2796-2809.
7. Iaquinta PJ, Lees JA: **Life and death decisions by the E2F transcription factors.** *Curr Opin Cell Biol* 2007, **19**:649-657.
8. Polager S, Ginsberg D: **E2F – at the crossroads of life and death.** *Trends Cell Biol* 2008, **18**:528-535.
9. Blais A, Dynlacht BD: **E2F-associated chromatin modifiers and cell cycle control.** *Curr Opin Cell Biol* 2007, **19**:658-662.
10. Blais A, Dynlacht BD: **Hitting their targets: an emerging picture of E2F and cell cycle control.** *Curr Opin Genet Dev* 2004, **14**:527-532.
11. Ohtani K: **Implication of transcription factor E2F in regulation of DNA replication.** *Front Biosci* 1999, **4**:D793-804.
12. Polager S, Kalma Y, Berkovich E, Ginsberg D: **E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis.** *Oncogene* 2002, **21**:437-446.
13. Stevens C, Smith L, La Thangue NB: **Chk2 activates E2F-1 in response to DNA damage.** *Nat Cell Biol* 2003, **5**:401-409.
14. Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH: **E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways.** *Mol Cell* 1999, **4**:771-781.
15. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH: **Induction of DNA synthesis and apoptosis are separable functions of E2F-1.** *Genes Dev* 1997, **11**:1853-1863.
16. Bell LA, Ryan KM: **Life and death decisions by E2F-1.** *Cell Death Differ* 2004, **11**:137-142.
17. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR: **E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis.** *J Virol* 1995, **69**:2491-2500.
18. Wu X, Levine AJ: **p53 and E2F-1 cooperate to mediate apoptosis.** *Proc Natl Acad Sci USA* 1994, **91**:3602-3606.
19. Skapek SX, Pan YR, Lee EY: **Regulation of cell lineage specification by the retinoblastoma tumor suppressor.** *Oncogene* 2006, **25**:5268-5276.
20. Korenjak M, Brehm A: **E2F-Rb complexes regulating transcription of genes important for differentiation and development.** *Curr Opin Genet Dev* 2005, **15**:520-527.
21. Galderisi U, Cipollaro M, Giordano A: **The retinoblastoma gene is involved in multiple aspects of stem cell biology.** *Oncogene* 2006, **25**:5250-5256.
22. Ben-Porath I, Weinberg RA: **The signals and pathways activating cellular senescence.** *Int J Biochem Cell Biol* 2005, **37**:961-976.
23. Gabellini C, Del Bufalo D, Zupi G: **Involvement of RB gene family in tumor angiogenesis.** *Oncogene* 2006, **25**:5326-5332.
24. Shan B, Chang CY, Jones D, Lee WH: **The transcription factor E2F-1 mediates the autoregulation of RB gene expression.** *Mol Cell Biol* 1994, **14**:299-309.
25. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T: **Retinoblastoma protein recruits histone deacetylase to repress transcription.** *Nature* 1998, **391**:597-601.
26. Magnaghi-Jaulin L, Groisman R, Naguibeva I, Robin P, Lorain S, Le Vilain JP, Trouche D, Harel-Bellan A: **Retinoblastoma protein represses transcription by recruiting a histone deacetylase.** *Nature* 1998, **391**:601-605.
27. Luo RX, Postigo AA, Dean DC: **Rb interacts with histone deacetylase to repress transcription.** *Cell* 1998, **92**:463-473.
28. Lai A, Lee JM, Yang WM, DeCaprio JA, Kaelin WG Jr, Seto E, Branton PE: **RBPI recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins.** *Mol Cell Biol* 1999, **19**:6632-6641.
29. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP: **The retinoblastoma protein and**

- BRG1 form a complex and cooperate to induce cell cycle arrest.** *Cell* 1994, **79**:119-130.
30. Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC: **Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF.** *Cell* 2000, **101**:79-89.
 31. Strober BE, Dunaief JL, Guha , Goff SP: **Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins.** *Mol Cell Biol* 1996, **16**:1576-1583.
 32. Xiao B, Spencer J, Clements A, Ali-Khan N, Mittnacht S, Broceno C, Burghammer M, Perrakis A, Marmorstein R, Gamblin SJ: **Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation.** *Proc Natl Acad Sci USA* 2003, **100**:2363-2368.
 33. Chan HM, Smith L, La Thangue NB: **Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein.** *Oncogene* 2001, **20**:6152-6163.
 34. Dahiya A, Gavin MR, Luo RX, Dean DC: **Role of the LXCXE binding site in Rb function.** *Mol Cell Biol* 2000, **20**:6799-6805.
 35. Singh M, Krajewski M, Mikolajka A, Holak TA: **Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences.** *J Biol Chem* 2005, **280**:37868-37876.
 36. Kim HY, Ahn BY, Cho Y: **Structural basis for the inactivation of retinoblastoma tumor suppressor by SV40 large T antigen.** *Embo J* 2001, **20**:295-304.
 37. Lee JO, Russo AA, Pavletich NP: **Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7.** *Nature* 1998, **391**:859-865.
 38. Bregman DB, Pestell RG, Kidd VJ: **Cell cycle regulation and RNA polymerase II.** *Front Biosci* 2000, **5**:D244-257.
 39. Hirose Y, Ohkuma Y: **Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression.** *J Biochem* 2007, **141**:601-608.
 40. Canduri F, Perez PC, Caceres RA, de Azevedo WF Jr: **CDK9 a potential target for drug development.** *Med Chem* 2008, **4**:210-218.
 41. Shapiro GI: **Cyclin-dependent kinase pathways as targets for cancer treatment.** *J Clin Oncol* 2006, **24**:1770-1783.
 42. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC: **Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.** *Cell* 1999, **98**:859-869.
 43. Buchkovich K, Duffy LA, Harlow E: **The retinoblastoma protein is phosphorylated during specific phases of the cell cycle.** *Cell* 1989, **58**:1097-1105.
 44. Adams PD: **Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks.** *Biochim Biophys Acta* 2001, **1471**:M123-133.
 45. Lundberg AS, Weinberg RA: **Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.** *Mol Cell Biol* 1998, **18**:753-761.
 46. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA: **Physical interaction of the retinoblastoma protein with human D cyclins.** *Cell* 1993, **73**:499-511.
 47. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM: **Functional interactions of the retinoblastoma protein with mammalian D-type cyclins.** *Cell* 1993, **73**:487-497.
 48. Kato J, Matsushime H, Hiebert SV, Ewen ME, Sherr CJ: **Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.** *Genes Dev* 1993, **7**:331-342.
 49. Adams PD, Li X, Sellers WR, Baker KB, Leng X, Harper JW, Taya Y, Kaelin WG Jr: **Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes.** *Mol Cell Biol* 1999, **19**:1068-1080.
 50. Besson A, Dowdy SF, Roberts JM: **CDK inhibitors: cell cycle regulators and beyond.** *Dev Cell* 2008, **14**:159-169.
 51. Sherr CJ, Roberts JM: **CDK inhibitors: positive and negative regulators of G1-phase progression.** *Genes Dev* 1999, **13**:1501-1512.
 52. Ludlow JW, Shon J, Pipas JM, Livingston DM, DeCaprio JA: **The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T.** *Cell* 1990, **60**:387-396.
 53. Ludlow JW, Glendening CL, Livingston DM, DeCaprio JA: **Specific enzymatic dephosphorylation of the retinoblastoma protein.** *Mol Cell Biol* 1993, **13**:367-372.
 54. Vietri M, Bianchi M, Ludlow JW, Mittnacht S, Villa-Moruzzi E: **Direct interaction between the catalytic subunit of Protein Phosphatase I and pRb.** *Cancer Cell Int* 2006, **6**:3.
 55. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, Mayer RJ, Arii S, Fujita J: **Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas.** *Nat Med* 2000, **6**:96-99.
 56. Nakamura Y, Nakano K, Umehara T, Kimura M, Hayashizaki Y, Tanaka A, Horikoshi M, Padmanabhan B, Yokoyama S: **Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome.** *Structure* 2007, **15**:179-189.
 57. Sherr CJ: **Cancer cell cycles.** *Science* 1996, **274**:1672-1677.
 58. Santamaria D, Ortega S: **Cyclins and CDKS in development and cancer: lessons from genetically modified mice.** *Front Biosci* 2006, **11**:1164-1188.
 59. Ortega S, Malumbres M, Barbacid M: **Cyclin D-dependent kinases, INK4 inhibitors and cancer.** *Biochim Biophys Acta* 2002, **1602**:73-87.
 60. Palmero I, Peters G: **Perturbation of cell cycle regulators in human cancer.** *Cancer Surv* 1996, **27**:351-367.
 61. Malumbres M, Barbacid M: **To cycle or not to cycle: a critical decision in cancer.** *Nat Rev Cancer* 2001, **1**:222-231.
 62. Munger K: **The role of human papillomaviruses in human cancers.** *Front Biosci* 2002, **7**:d641-649.
 63. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D: **A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.** *Science* 1995, **269**:1281-1284.
 64. Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, Goldstein A, Puig S, Mackie R, Elder D, Hansson J, Hayward N, Hogg D, Olsson H: **Genetic testing for melanoma.** *Lancet Oncol* 2002, **3**:653-654.
 65. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL: **Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.** *Nature* 1983, **305**:779-784.
 66. Classon M, Dyson N: **p107 and p130: versatile proteins with interesting pockets.** *Exp Cell Res* 2001, **264**:135-147.
 67. Grana X, Garriga J, Mayol X: **Role of the retinoblastoma protein family, pRb, p107 and p130 in the negative control of cell growth.** *Oncogene* 1998, **17**:3365-3383.
 68. Mayol X, Garriga J, Grana X: **Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130.** *Oncogene* 1995, **11**:801-808.
 69. Tedesco D, Lukas J, Reed SI: **The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2).** *Genes Dev* 2002, **16**:2946-2957.
 70. Mittnacht S: **Control of pRB phosphorylation.** *Curr Opin Genet Dev* 1998, **8**:21-27.
 71. Howard CM, Claudio PP, De Luca A, Stiegler P, Jori FP, Safdar NM, Caputi M, Khalili K, Giordano A: **Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop.** *Cancer Res* 2000, **60**:2737-2744.
 72. Claudio PP, Howard CM, Fu Y, Cinti C, Califano L, Micheli P, Mercer EW, Caputi M, Giordano A: **Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma.** *Cancer Res* 2000, **60**:8-12.
 73. Claudio PP, Caputi M, Giordano A: **The RB2/p130 gene: the latest weapon in the war against lung cancer?** *Clin Cancer Res* 2000, **6**:754-764.
 74. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, Maraldi NM, Minna JD, Gelbert L, Leoncini L, Tosi GM, Hicheli P, Caputi M, Giordano GG, Giordano A: **Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer.** *Cancer Res* 2000, **60**:372-382.
 75. Yeung RS, Bell DW, Testa JR, Mayol X, Baldi A, Grana X, Klinga-Levan K, Knudson AG, Giordano A: **The retinoblastoma-related gene,**

- RB2, maps to human chromosome 16q12 and rat chromosome 19.** *Oncogene* 1993, **8**:3465-3468.
76. Scambia G, Lovergine S, Masciullo V: **RB family members as predictive and prognostic factors in human cancer.** *Oncogene* 2006, **25**:5302-5308.
 77. Felsani A, Mileo AM, Paggi MG: **Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins.** *Oncogene* 2006, **25**:5277-5285.
 78. Helt AM, Galloway DA: **Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.** *Carcinogenesis* 2003, **24**:159-169.
 79. Lee C, Cho Y: **Interactions of SV40 large T antigen and other viral proteins with retinoblastoma tumour suppressor.** *Rev Med Virol* 2002, **12**:81-92.
 80. Raychaudhuri P, Bagchi S, Devoto SH, Kraus VB, Moran E, Nevins JR: **Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes.** *Genes Dev* 1991, **5**:1200-1211.
 81. Liu X, Marmorstein R: **Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor.** *Genes Dev* 2007, **21**:2711-2716.
 82. Ikeda MA, Nevins JR: **Identification of distinct roles for separate E1A domains in disruption of E2F complexes.** *Mol Cell Biol* 1993, **13**:7029-7035.
 83. Gustafsson B, Huang W, Bogdanovic G, Gauffin F, Nordgren A, Talekar G, Ornelles DA, Gooding LR: **Adenovirus DNA is detected at increased frequency in Guthrie cards from children who develop acute lymphoblastic leukaemia.** *Br J Cancer* 2007, **97**:992-994.
 84. Berezutskaya E, Yu B, Morozov A, Raychaudhuri P, Bagchi S: **Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein.** *Cell Growth Differ* 1997, **8**:1277-1286.
 85. Boyer SN, Wazer DE, Band V: **E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway.** *Cancer Res* 1996, **56**:4620-4624.
 86. Jones DL, Munger K: **Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein.** *J Virol* 1997, **71**:2905-2912.
 87. Gonzalez SL, Stremelau M, He X, Basile JR, Munger K: **Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.** *J Virol* 2001, **75**:7583-7591.
 88. Helt AM, Galloway DA: **Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.** *J Virol* 2001, **75**:6737-6747.
 89. Vousden KH: **Interactions between papillomavirus proteins and tumor suppressor gene products.** *Adv Cancer Res* 1994, **64**:1-24.
 90. Berezutskaya E, Bagchi S: **The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome.** *J Biol Chem* 1997, **272**:30135-30140.
 91. Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J, Harper JW, Munger K: **Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor.** *J Virol* 2007, **81**:9737-9747.
 92. Heck DV, Yee CL, Howley PM, Munger K: **Efficiency of binding of the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses.** *Proc Natl Acad Sci USA* 1992, **89**:4442-4446.
 93. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM: **SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.** *Cell* 1988, **54**:275-283.
 94. Zalvide J, DeCaprio JA, Stubbald H: **Binding of SV40 large T antigen to the retinoblastoma susceptibility gene product and related proteins.** *Methods Mol Biol* 2001, **165**:213-218.
 95. Zalvide J, DeCaprio JA: **Role of pRb-related proteins in simian virus 40 large-T-antigen-mediated transformation.** *Mol Cell Biol* 1995, **15**:5800-5810.
 96. Zalvide J, Stubbald H, DeCaprio JA: **The J domain of simian virus 40 large T antigen is required to functionally inactivate RB family proteins.** *Mol Cell Biol* 1998, **18**:1408-1415.
 97. Sullivan CS, Cantalupo P, Pipas JM: **The molecular chaperone activity of simian virus 40 large T antigen is required to disrupt Rb-E2F family complexes by an ATP-dependent mechanism.** *Mol Cell Biol* 2000, **20**:6233-6243.
 98. Stubbald H, Zalvide J, DeCaprio JA: **Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107.** *J Virol* 1996, **70**:2781-2788.
 99. Leithner K, Leithner A, Clar H, Weinhaeusel A, Radl R, Krippel P, Rehak P, Windhager R, Haas OA, Olschewski H: **Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40.** *Orphanet J Rare Dis* 2006, **1**:44.
 100. DeCaprio JA: **The role of the J domain of SV40 large T in cellular transformation.** *Biologicals* 1999, **27**:23-28.
 101. Lin JY, DeCaprio JA: **SV40 large T antigen promotes dephosphorylation of p130.** *J Biol Chem* 2003, **278**:46482-46487.
 102. Lundstig A, Dejmek A, Eklund C, Filinic I, Dillner J: **No detection of SV40 DNA in mesothelioma tissues from a high incidence area in Sweden.** *Anticancer Res* 2007, **27**:4159-4161.
 103. Saric M, Curin K, Varnai VM: **The role of polio-vaccine in pleural mesothelioma – an epidemiological observation.** *Coll Antropol* 2008, **32**:479-483.
 104. Pellett PE, Roizman B: **The Family: Herpesviridae A Brief Introduction.** In *Fields Virology Volume II*. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2007:2479-2499.
 105. Grunewald K, Desai P, Winkler DC, Heymann JB, Belnap DM, Baumeister W, Steven AC: **Three-dimensional structure of herpes simplex virus from cryo-electron tomography.** *Science* 2003, **302**:1396-1398.
 106. Liu F, Zhou ZH: **Comparative virion structures of human herpesviruses.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:27-43.
 107. Kalejta RF: **Tegument proteins of human cytomegalovirus.** *Microbiol Mol Biol Rev* 2008, **72**:249-265.
 108. McGeoch DJ, Rixon FJ, Davison AJ: **Topics in herpesvirus genomics and evolution.** *Virus Res* 2006, **117**:90-104.
 109. Davison AJ: **Comparative analysis of the genomes.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:10-26.
 110. Taylor TJ, Brockman MA, McNamee EE, Knipe DM: **Herpes simplex virus.** *Front Biosci* 2002, **7**:d752-764.
 111. Mocarski ES: **Comparative analysis of herpesvirus-common proteins.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:44-58.
 112. Mori I, Nishiyama Y: **Herpes simplex virus and varicella-zoster virus: why do these human alphaherpesviruses behave so differently from one another?** *Rev Med Virol* 2005, **15**:393-406.
 113. Steiner I, Kennedy PG, Pachner AR: **The neurotropic herpes viruses: herpes simplex and varicella-zoster.** *Lancet Neurol* 2007, **6**:1015-1028.
 114. Looker KJ, Garnett GP, Schmid GP: **An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.** *Bull World Health Organ* 2008, **86**:805-812.
 115. Song B, Liu JJ, Yeh KC, Knipe DM: **Herpes simplex virus infection blocks events in the G1 phase of the cell cycle.** *Virology* 2000, **267**:326-334.
 116. de Bruyn Kops A, Knipe DM: **Formation of DNA replication structures in herpes virus-infected cells requires a viral DNA binding protein.** *Cell* 1988, **55**:857-868.
 117. Ehmann GL, McLean TI, Bachenheimer SL: **Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells.** *Virology* 2000, **267**:335-349.
 118. Olgiate J, Ehmann GL, Vidyarthi S, Hilton MJ, Bachenheimer SL: **Herpes simplex virus induces intracellular redistribution of E2F4 and accumulation of E2F pocket protein complexes.** *Virology* 1999, **258**:257-270.
 119. Song B, Yeh KC, Liu J, Knipe DM: **Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions.** *Virology* 2001, **290**:320-328.
 120. Sandri-Goldin RM: **The many roles of the regulatory protein ICP27 during herpes simplex virus infection.** *Front Biosci* 2008, **13**:5241-5256.
 121. Smiley JR, Elgadi MM, Saffran HA: **Herpes simplex virus vhs protein.** *Methods Enzymol* 2001, **342**:440-451.

122. Sandri-Goldin RM, Mendoza GE: **A herpesvirus regulatory protein appears to act post-transcriptionally by affecting mRNA processing.** *Genes Dev* 1992, **6**:848-863.
123. Sandri-Goldin RM: **Properties of an HSV-1 regulatory protein that appears to impair host cell splicing.** *Infect Agents Dis* 1994, **3**:59-67.
124. Hardy WR, Sandri-Goldin RM: **Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect.** *J Virol* 1994, **68**:7790-7799.
125. Hobbs WE 2nd, DeLuca NA: **Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0.** *J Virol* 1999, **73**:8245-8255.
126. Lomonte P, Everett RD: **Herpes simplex virus type I immediate-early protein Vmw110 inhibits progression of cells through mitosis and from G(1) into S phase of the cell cycle.** *J Virol* 1999, **73**:9456-9467.
127. Hossain A, Holt T, Ciacci-Zanella J, Jones C: **Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.** *J Gen Virol* 1997, **78**(Pt 12):3341-3348.
128. Ehmann GL, Burnett HA, Bachenheimer SL: **Pocket protein p130/Rb2 is required for efficient herpes simplex virus type I gene expression and viral replication.** *J Virol* 2001, **75**:7149-7160.
129. Hilton MJ, Mounghane D, McLean T, Contractor NV, O'Neil J, Carpenter K, Bachenheimer SL: **Induction by herpes simplex virus of free and heteromeric forms of E2F transcription factor.** *Virology* 1995, **213**:624-638.
130. Sacks WR, Schaffer PA: **Deletion mutants in the gene encoding the herpes simplex virus type I immediate-early protein ICP0 exhibit impaired growth in cell culture.** *J Virol* 1987, **61**:829-839.
131. Stow ND, Stow EC: **Isolation and characterization of a herpes simplex virus type I mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110.** *J Gen Virol* 1986, **67**(Pt 12):2571-2585.
132. Lacy S, Whyte P: **Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes.** *Oncogene* 1997, **14**:2395-2406.
133. Zhu L, Enders G, Lees JA, Beijersbergen RL, Bernards R, Harlow E: **The pRB-related protein p107 contains two growth suppression domains: independent interactions with E2F and cyclin/cdk complexes.** *Emboj* 1995, **14**:1904-1913.
134. Zhu L, Harlow E, Dynlacht BD: **p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.** *Genes Dev* 1995, **9**:1740-1752.
135. Shirodkar S, Ewen M, DeCaprio JA, Morgan J, Livingston DM, Chittenden T: **The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner.** *Cell* 1992, **68**:157-166.
136. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T: **Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.** *Nature* 2003, **424**:223-228.
137. Schang LM, Phillips J, Schaffer PA: **Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.** *J Virol* 1998, **72**:5626-5637.
138. Diwan P, Lacasse JJ, Schang LM: **Roscovetine inhibits activation of promoters in herpes simplex virus type I genomes independently of promoter-specific factors.** *J Virol* 2004, **78**:9352-9365.
139. Durand LO, Roizman B: **Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus I.** *J Virol* 2008, **82**:10591-10599.
140. Davido DJ, Von Zagorski WF, Maul GG, Schaffer PA: **The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type I ICP0.** *J Virol* 2003, **77**:12603-12616.
141. Advani SJ, Weichselbaum RR, Roizman B: **E2F proteins are post-translationally modified concomitantly with a reduction in nuclear binding activity in cells infected with herpes simplex virus I.** *J Virol* 2000, **74**:7842-7850.
142. Leisenfelder SA, Moffat JF: **Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity.** *J Virol* 2006, **80**:5577-5587.
143. Moffat JF, McMichael MA, Leisenfelder SA, Taylor SL: **Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis.** *Biochim Biophys Acta* 2004, **1697**:225-231.
144. Taylor SL, Kinchington PR, Brooks A, Moffat JF: **Roscovetine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.** *J Virol* 2004, **78**:2853-2862.
145. Leisenfelder SA, Kinchington PR, Moffat JF: **Cyclin Dependent Kinase 1/Cyclin B1 Phosphorylates Varicella-Zoster Virus IE62 and is Incorporated into Virions.** *J Virol* 2008, **82**:12116-12125.
146. De Bolle L, Naesens L, De Clercq E: **Update on human herpesvirus 6 biology, clinical features, and therapy.** *Clin Microbiol Rev* 2005, **18**:217-245.
147. Caselli E, Di Luca D: **Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7.** *New Microbiol* 2007, **30**:173-187.
148. Black JB, Pellett PE: **Human herpesvirus 7.** *Rev Med Virol* 1999, **9**:245-262.
149. Braun DK, Dominguez G, Pellett PE: **Human herpesvirus 6.** *Clin Microbiol Rev* 1997, **10**:521-567.
150. Mori Y, Yamanishi K: **HHV-6A, 6B, and 7: pathogenesis, host response, and clinical disease.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:833-842.
151. Vancikova Z, Dvorak P: **Cytomegalovirus infection in immunocompetent and immunocompromised individuals – a review.** *Curr Drug Targets Immune Endocr Metabol Disord* 2001, **1**:179-187.
152. Boppana S, Fowler K: **CMV: persistence in the population: epidemiology and transmission.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:795-813.
153. Emery V, Clark D: **HHV-6A, 6B, and 7: persistence in the population: epidemiology, transmission.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:875-881.
154. Britt WJ: **CMV: pathogenesis and disease consequences.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:737-764.
155. Castillo JP, Kowalik TF: **CMV infection: modulating the cell cycle and cell death.** *Int Rev Immunol* 2004, **23**:113-139.
156. Jault FM, Jault JM, Ruchti F, Fortunato EA, Clark C, Corbeil J, Richman DD, Spector DH: **Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.** *J Virol* 1995, **69**:6697-6704.
157. Sinclair J, Baillie J, Bryant L, Caswell R: **Human cytomegalovirus mediates cell cycle progression through G(1) into early S phase in terminally differentiated cells.** *J Gen Virol* 2000, **81**:1553-1565.
158. Kalejta RF, Shenk T: **Manipulation of the cell cycle by human cytomegalovirus.** *Front Biosci* 2002, **7**:d295-306.
159. Bresnahan WA, Boldogh I, Thompson EA, Albrecht T: **Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1.** *Virology* 1996, **224**:150-160.
160. Dittmer D, Mocarski ES: **Human cytomegalovirus infection inhibits G1/S transition.** *J Virol* 1997, **71**:1629-1634.
161. Salvant BS, Fortunato EA, Spector DH: **Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription.** *J Virol* 1998, **72**:3729-3741.
162. Lu M, Shenk T: **Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S.** *J Virol* 1996, **70**:8850-8857.
163. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF: **Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.** *Science* 2008, **320**:797-799.
164. Kalejta RF: **Functions of human cytomegalovirus tegument proteins prior to immediate early gene expression.** *Curr Top Microbiol Immunol* 2008, **325**:101-115.
165. Kalejta RF, Shenk T: **Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.** *Proc Natl Acad Sci USA* 2003, **100**:3263-3268.
166. Kalejta RF, Bechtel JT, Shenk T: **Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors.** *Mol Cell Biol* 2003, **23**:1885-1895.

167. Kalejta RF, Shenk T: **The human cytomegalovirus UL82 gene product (pp71) accelerates progression through the G1 phase of the cell cycle.** *J Virol* 2003, **77**:3451-3459.
168. Kalejta RF: **Human cytomegalovirus pp71: a new viral tool to probe the mechanisms of cell cycle progression and oncogenesis controlled by the retinoblastoma family of tumor suppressors.** *J Cell Biochem* 2004, **93**:37-45.
169. Cantrell SR, Bresnahan WA: **Interaction between the human cytomegalovirus UL82 gene product (pp71) and hDaxx regulates immediate-early gene expression and viral replication.** *J Virol* 2005, **79**:7792-7802.
170. Saffert RT, Kalejta RF: **Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression.** *J Virol* 2006, **80**:3863-3871.
171. Cantrell SR, Bresnahan WA: **Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication.** *J Virol* 2006, **80**:6188-6191.
172. Preston CM, Nicholl MJ: **Role of the cellular protein hDaxx in human cytomegalovirus immediate-early gene expression.** *J Gen Virol* 2006, **87**:1113-1121.
173. Saffert RT, Kalejta RF: **Promyelocytic leukemia-nuclear body proteins: herpesvirus enemies, accomplices or both?** *Future Virology* 2008, **3**:265-277.
174. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T: **Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections.** *J Virol* 2006, **80**:8006-8018.
175. Woodhall DL, Groves IJ, Reeves MB, Wilkinson G, Sinclair JH: **Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter.** *J Biol Chem* 2006, **281**:37652-37660.
176. Saffert RT, Kalejta RF: **Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro.** *J Virol* 2007, **81**:9109-9120.
177. Hwang J, Kalejta RF: **Proteasome-dependent, ubiquitin-independent degradation of Daxx by the viral pp71 protein in human cytomegalovirus-infected cells.** *Virology* 2007, **367**:334-338.
178. Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, Parker BO, Pari GS: **A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency.** *J Virol* 1999, **73**:5663-5670.
179. He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM: **The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines.** *J Virol* 1997, **71**:405-411.
180. Prichard MN, Sztul E, Daily SL, Perry AL, Frederick SL, Gill RB, Hartline CB, Strebblow DN, Varnum SM, Smith RD, Kern ER: **Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes.** *J Virol* 2008, **82**:5054-5067.
181. Wolf DG, Courcelle CT, Prichard MN, Mocarski ES: **Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation.** *Proc Natl Acad Sci USA* 2001, **98**:1895-1900.
182. Prichard MN, Britt WJ, Daily SL, Hartline CB, Kern ER: **Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis.** *J Virol* 2005, **79**:15494-15502.
183. Kamil JP, Coen DM: **Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65.** *J Virol* 2007, **81**:10659-10668.
184. Marschall M, Marzi A, aus dem Siepen P, Jochmann R, Kalmr M, Auerochs S, Lischka P, Leis M, Stamminger T: **Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina.** *J Biol Chem* 2005, **280**:33357-33367.
185. Littler E, Stuart AD, Chee MS: **Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir.** *Nature* 1992, **358**:160-162.
186. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK: **A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.** *Nature* 1992, **358**:162-164.
187. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW: **Potent and selective inhibition of human cytomegalovirus replication by I263W94, a benzimidazole L-riboside with a unique mode of action.** *Antimicrob Agents Chemother* 2002, **46**:2365-2372.
188. Biron KK: **Antiviral drugs for cytomegalovirus diseases.** *Antiviral Res* 2006, **71**:154-163.
189. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD: **Maribavir: a novel antiviral agent with activity against cytomegalovirus.** *Ann Pharmacother* 2008, **42**:1447-1457.
190. Chou S, Marousek GI: **Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.** *Antimicrob Agents Chemother* 2006, **50**:3470-3472.
191. Mocarski ES, Kemble GW, Lyle JM, Greaves RF: **A deletion mutant in the human cytomegalovirus gene encoding IE1(491aa) is replication defective due to a failure in autoregulation.** *Proc Natl Acad Sci USA* 1996, **93**:11321-11326.
192. Greaves RF, Mocarski ES: **Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant.** *J Virol* 1998, **72**:366-379.
193. Castillo JP, Yurochko AD, Kowalik TF: **Role of human cytomegalovirus immediate-early proteins in cell growth control.** *J Virol* 2000, **74**:8028-8037.
194. Castillo JP, Frame FM, Rogoff HA, Pickering MT, Yurochko AD, Kowalik TF: **Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrest response.** *J Virol* 2005, **79**:11467-11475.
195. Poma EE, Kowalik TF, Zhu L, Sinclair JH, Huang ES: **The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter.** *J Virol* 1996, **70**:7867-7877.
196. Zhang Z, Huang SM, Wang X, Huang DY, Huang ES: **Interactions between human cytomegalovirus IE1-72 and cellular p107: functional domains and mechanisms of up-regulation of cyclin E/cdk2 kinase activity.** *J Virol* 2003, **77**:12660-12670.
197. Chiou CJ, Zong J, Waheed I, Hayward GS: **Identification and mapping of dimerization and DNA-binding domains in the C terminus of the IE2 regulatory protein of human cytomegalovirus.** *J Virol* 1993, **67**:6201-6214.
198. Pajovic S, Wong EL, Black AR, Azizkhan JC: **Identification of a viral kinase that phosphorylates specific E2Fs and pocket proteins.** *Mol Cell Biol* 1997, **17**:6459-6464.
199. Marchini A, Liu H, Zhu H: **Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes.** *J Virol* 2001, **75**:1870-1878.
200. Hagemeyer C, Caswell R, Hayhurst G, Sinclair J, Kouzarides T: **Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.** *Embo J* 1994, **13**:2897-2903.
201. Fortunato EA, Sommer MH, Yoder K, Spector DH: **Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other.** *J Virol* 1997, **71**:8176-8185.
202. Sommer MH, Scully AL, Spector DH: **Transactivation by the human cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the TATA box-binding protein and the retinoblastoma protein.** *J Virol* 1994, **68**:6223-6231.
203. Bresnahan WA, Albrecht T, Thompson EA: **The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein.** *J Biol Chem* 1998, **273**:22075-22082.
204. Wiebusch L, Asmar J, Uecker R, Hagemeyer C: **Human cytomegalovirus immediate-early protein 2 (IE2)-mediated activation of cyclin E is cell-cycle-independent and forces S-phase entry in IE2-arrested cells.** *J Gen Virol* 2003, **84**:51-60.
205. White EA, Spector DH: **Exon 3 of the human cytomegalovirus major immediate-early region is required for efficient viral gene expression and for cellular cyclin modulation.** *J Virol* 2005, **79**:7438-7452.
206. Wiebusch L, Hagemeyer C: **Human cytomegalovirus 86-kilodalton IE2 protein blocks cell cycle progression in G(1).** *J Virol* 1999, **73**:9274-9283.

207. Murphy EA, Streblov DN, Nelson JA, Stinski MF: **The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells.** *J Virol* 2000, **74**:7108-7118.
208. Song YJ, Stinski MF: **Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis.** *Proc Natl Acad Sci USA* 2002, **99**:2836-2841.
209. McElroy AK, Dwarakanath RS, Spector DH: **Dysregulation of cyclin E gene expression in human cytomegalovirus-infected cells requires viral early gene expression and is associated with changes in the Rb-related protein p130.** *J Virol* 2000, **74**:4192-4206.
210. Secchiero P, Bertolaso L, Casareto L, Gibellini D, Vitale M, Bemis K, Aleotti A, Capitani S, Franchini G, Gallo RC, Zauli G: **Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to dysregulation of cdc2 and cyclin B and polyploidization of CD4(+) T cells.** *Blood* 1998, **92**:1685-1696.
211. Oster B, Bundgaard B, Hollberg P: **Human herpesvirus 6B induces cell cycle arrest concomitant with p53 phosphorylation and accumulation in T cells.** *J Virol* 2005, **79**:1961-1965.
212. Oster B, Kaspersen MD, Kofod-Olsen E, Bundgaard B, Hollberg P: **Human herpesvirus 6B inhibits cell proliferation by a p53-independent pathway.** *J Clin Virol* 2006, **37**(Suppl 1):S63-68.
213. Dietrich J, Blumberg BM, Roshal M, Baker JV, Hurley SD, Mayer-Proschel M, Mock DJ: **Infection with an endemic human herpesvirus disrupts critical glial precursor cell properties.** *J Neurosci* 2004, **24**:4875-4883.
214. Kalejta RF, Brideau AD, Banfield BW, Beavis AJ: **An integral membrane green fluorescent protein marker, Us9-GFP, is quantitatively retained in cells during propidium iodide-based cell cycle analysis by flow cytometry.** *Exp Cell Res* 1999, **248**:322-328.
215. Kalejta RF, Shenk T, Beavis AJ: **Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry.** *Cytometry* 1997, **29**:286-291.
216. Oster B, Kofod-Olsen E, Bundgaard B, Hollberg P: **Restriction of human herpesvirus 6B replication by p53.** *J Gen Virol* 2008, **89**:1106-1113.
217. De Bolle L, Hatse S, Verbeken E, De Clercq E, Naesens L: **Human herpesvirus 6 infection arrests cord blood mononuclear cells in G(2) phase of the cell cycle.** *FEBS Lett* 2004, **560**:25-29.
218. Bresnahan WA, Boldogh I, Chi P, Thompson EA, Albrecht T: **Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication.** *Virology* 1997, **231**:239-247.
219. Evers DL, Breitenbach JM, Borysko KZ, Townsend LB, Drach JC: **Inhibition of cyclin-dependent kinase I by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.** *Antimicrob Agents Chemother* 2002, **46**:2470-2476.
220. Sanchez V, McElroy AK, Yen J, Tamrakar S, Clark CL, Schwartz RA, Spector DH: **Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production.** *J Virol* 2004, **78**:11219-11232.
221. Sanchez V, Spector DH: **Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles.** *J Virol* 2006, **80**:5886-5896.
222. Soderberg-Naucler C: **Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?** *J Intern Med* 2006, **259**:219-246.
223. Goldmacher VS: **Cell death suppression by cytomegaloviruses.** *Apoptosis* 2005, **10**:251-265.
224. Michaelis M, Kotchetkov R, Vogel JU, Doerr HW, Cinatl J Jr: **Cytomegalovirus infection blocks apoptosis in cancer cells.** *Cell Mol Life Sci* 2004, **61**:1307-1316.
225. Shen Y, Zhu H, Shenk T: **Human cytomegalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins.** *Proc Natl Acad Sci USA* 1997, **94**:3341-3345.
226. Hayashi ML, Blankenship C, Shenk T: **Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle.** *Proc Natl Acad Sci USA* 2000, **97**:2692-2696.
227. Lu M, Shenk T: **Human cytomegalovirus UL69 protein induces cells to accumulate in G1 phase of the cell cycle.** *J Virol* 1999, **73**:676-683.
228. Araujo JC, Doniger J, Kashanchi F, Hermonat PL, Thompson J, Rosenthal LJ: **Human herpesvirus 6A ts suppresses both trans-formation by H-ras and transcription by the H-ras and human immunodeficiency virus type I promoters.** *J Virol* 1995, **69**:4933-4940.
229. Kutok JL, Wang F: **Spectrum of Epstein-Barr virus-associated diseases.** *Annu Rev Pathol* 2006, **1**:375-404.
230. Kuppers R: **B cells under influence: transformation of B cells by Epstein-Barr virus.** *Nat Rev Immunol* 2003, **3**:801-812.
231. Ambinder R, Cesarman E: **Clinical and pathological aspects of EBV and KSHV infection.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:885-903.
232. Kieff ED, Rickinson AB: **Epstein-Barr Virus and Its Replication.** In *Fields Virology Volume II*. Fifth edition. Philadelphia: Lippincott Williams & Wilkins; 2007:2603-2654.
233. Rickinson AB, Kieff ED: **Epstein-Barr Virus.** In *Fields Virology Volume II*. Fifth edition. Philadelphia: Lippincott Williams & Wilkins; 2007:2655-2700.
234. Ganem D: **Kaposi's Sarcoma-Associated Herpesvirus.** In *Fields Virology Volume II*. Fifth edition. Philadelphia: Lippincott Williams & Wilkins; 2007:2847-2888.
235. Ganem D: **KSHV infection and the pathogenesis of Kaposi's sarcoma.** *Annu Rev Pathol* 2006, **1**:273-296.
236. Thorley-Lawson DA, Allday MJ: **The curious case of the tumour virus: 50 years of Burkitt's lymphoma.** *Nat Rev Microbiol* 2008, **6**:913-924.
237. Nicholas J: **Human herpesvirus 8-encoded proteins with potential roles in virus-associated neoplasia.** *Front Biosci* 2007, **12**:265-281.
238. Tao Q, Young LS, Woodman CB, Murray PG: **Epstein-Barr virus (EBV) and its associated human cancers – genetics, epigenetics, pathobiology and novel therapeutics.** *Front Biosci* 2006, **11**:2672-2713.
239. Du MQ, Bacon CM, Isaacson PG: **Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.** *J Clin Pathol* 2007, **60**:1350-1357.
240. Cannell EJ, Farrell PJ, Sinclair AJ: **Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells.** *Oncogene* 1996, **13**:1413-1421.
241. Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G, Farrell PJ: **Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus.** *J Virol* 1999, **73**:4678-4688.
242. Yates JL, Warren N, Sugden B: **Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.** *Nature* 1985, **313**:812-815.
243. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG: **EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins.** *Proc Natl Acad Sci USA* 1993, **90**:5455-5459.
244. Inman GJ, Farrell PJ: **Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays.** *J Gen Virol* 1995, **76**(Pt 9):2141-2149.
245. Sinclair AJ, Palmero I, Peters G, Farrell PJ: **EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus.** *Embo J* 1994, **13**:3321-3328.
246. Arvanitakis L, Yaseen N, Sharma S: **Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells.** *J Immunol* 1995, **155**:1047-1056.
247. Dirmeier U, Hoffmann R, Kilger E, Schultheiss U, Briseno C, Gires O, Kieser A, Eick D, Sugden B, Hammerschmidt W: **Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis.** *Oncogene* 2005, **24**:1711-1717.
248. Yang X, He Z, Xin B, Cao L: **LMPI of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16INK4a expression.** *Oncogene* 2000, **19**:2002-2013.
249. Ohtani N, Brennan P, Gaubatz S, Sanij E, Hertzog P, Wolvetang E, Ghysdael J, Rowe M, Hara E: **Epstein-Barr virus LMPI blocks**

- p16INK4a-RB pathway by promoting nuclear export of E2F4/5.** *J Cell Biol* 2003, **162**:173-183.
250. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, Allday MJ: **Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7.** *Oncogene* 1996, **13**:2541-2549.
251. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, Takada K: **Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells.** *Proc Natl Acad Sci USA* 2006, **103**:19500-19505.
252. Kashuba E, Yurchenko M, Yenamandra SP, Snopok B, Isagulians M, Szekeley L, Klein G: **EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes.** *Proc Natl Acad Sci USA* 2008, **105**:5489-5494.
253. Knight JS, Robertson ES: **Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity.** *J Virol* 2004, **78**:1981-1991.
254. Knight JS, Sharma N, Kalman DE, Robertson ES: **A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells.** *J Virol* 2004, **78**:12857-12867.
255. Knight JS, Sharma N, Robertson ES: **SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen.** *Mol Cell Biol* 2005, **25**:1749-1763.
256. Knight JS, Sharma N, Robertson ES: **Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase.** *Proc Natl Acad Sci USA* 2005, **102**:18562-18566.
257. Ji P, Jiang H, Rehtman K, Bloom J, Ichetovkin M, Pagano M, Zhu L: **An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant.** *Mol Cell* 2004, **16**:47-58.
258. Binne UK, Classon MK, Dick FA, Wei W, Rape M, Kaelin WG Jr, Naar AM, Dyson NJ: **Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit.** *Nat Cell Biol* 2007, **9**:225-232.
259. Kudoh A, Fujita M, Kiyono T, Kuzushima K, Sugaya Y, Izuta S, Nishiyama Y, Tsurumi T: **Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication.** *J Virol* 2003, **77**:851-861.
260. Rodriguez A, Jung EJ, Flemington EK: **Cell cycle analysis of Epstein-Barr virus-infected cells following treatment with lytic cycle-inducing agents.** *J Virol* 2001, **75**:4482-4489.
261. Cayrol C, Flemington EK: **The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.** *Embo J* 1996, **15**:2748-2759.
262. Mauser A, Holley-Guthrie E, Zanation A, Yarborough W, Kaufmann W, Klingelutz A, Seaman WT, Kenney S: **The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells.** *J Virol* 2002, **76**:12543-12552.
263. Mauser A, Holley-Guthrie E, Simpson D, Kaufmann W, Kenney S: **The Epstein-Barr virus immediate-early protein BZLF1 induces both a G(2) and a mitotic block.** *J Virol* 2002, **76**:10030-10037.
264. Zacny VL, Wilson J, Pagano JS: **The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle.** *J Virol* 1998, **72**:8043-8051.
265. Swenson JJ, Mauser AE, Kaufmann WK, Kenney SC: **The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction.** *J Virol* 1999, **73**:6540-6550.
266. Liu C, Sista ND, Pagano JS: **Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F.** *J Virol* 1996, **70**:2545-2555.
267. Kudoh A, Daikoku T, Sugaya Y, Isomura H, Fujita M, Kiyono T, Nishiyama Y, Tsurumi T: **Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.** *J Virol* 2004, **78**:104-115.
268. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM: **Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.** *Microbiol Mol Biol Rev* 2003, **67**:175-212. table of contents
269. Radkov SA, Kellam P, Boshoff C: **The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells.** *Nat Med* 2000, **6**:1121-1127.
270. Fakhari FD, Jeong JH, Kanan Y, Dittmer DP: **The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.** *J Clin Invest* 2006, **116**:735-742.
271. Fujimuro M, Wu FY, Aprhys C, Kajumbula H, Young DB, Hayward GS, Hayward SD: **A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency.** *Nat Med* 2003, **9**:300-306.
272. Tang J, Gordon GM, Muller MG, Dahiya M, Foreman KE: **Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells.** *J Virol* 2003, **77**:5975-5984.
273. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM: **Id proteins in cell growth and tumorigenesis.** *Cancer Cell* 2003, **3**:525-530.
274. An FQ, Compitello N, Horwitz E, Sramkoski M, Knudsen ES, Renne R: **The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest.** *J Biol Chem* 2005, **280**:3862-3874.
275. Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, Chang Y, Knowles DM: **Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma.** *J Virol* 1996, **70**:8218-8223.
276. Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F, Jung JU: **Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin.** *J Virol* 1997, **71**:1984-1991.
277. Ojala PM, Tiainen M, Salven P, Veikkola T, Castanos-Velez E, Sarid R, Biberfeld P, Makela TP: **Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.** *Cancer Res* 1999, **59**:4984-4989.
278. Platt GM, Cannell E, Cuomo ME, Singh S, Mittnacht S: **Detection of the human herpesvirus 8-encoded cyclin protein in primary effusion lymphoma-derived cell lines.** *Virology* 2000, **272**:257-266.
279. Davis MA, Sturzl MA, Blasig C, Schreier A, Guo HG, Reitz M, Opalenik SR, Browning PJ: **Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells.** *J Natl Cancer Inst* 1997, **89**:1868-1874.
280. Ascherl G, Hohenadl C, Monini P, Zietz C, Browning PJ, Ensoli B, Sturzl M: **Expression of human herpesvirus-8 (HHV-8) encoded pathogenic genes in Kaposi's sarcoma (KS) primary lesions.** *Adv Enzyme Regul* 1999, **39**:331-339.
281. Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, Moore P, Weiss RA, Mittnacht S: **The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1.** *J Virol* 1997, **71**:4193-4198.
282. Jung JU, Stager M, Desrosiers RC: **Virus-encoded cyclin.** *Mol Cell Biol* 1994, **14**:7235-7244.
283. Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska K, Godden K, Paterson H, Weiss RA, Mittnacht S: **Cyclin encoded by KS herpesvirus.** *Nature* 1996, **382**:410.
284. Laman H, Mann DJ, Jones NC: **Viral-encoded cyclins.** *Curr Opin Genet Dev* 2000, **10**:70-74.
285. Mann DJ, Child ES, Swanton C, Laman H, Jones N: **Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus.** *Embo J* 1999, **18**:654-663.
286. Ellis M, Chew YP, Fallis L, Freddersdorf S, Boshoff C, Weiss RA, Lu X, Mittnacht S: **Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.** *Embo J* 1999, **18**:644-653.
287. Sarek G, Jarviluoma A, Ojala PM: **KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas.** *Blood* 2006, **107**:725-732.
288. Van Dross R, Yao S, Asad S, Westlake G, Mays DJ, Barquero L, Duell S, Pietsenpol JA, Browning PJ: **Constitutively active K-cyclin/cdk6**

- kinase in Kaposi sarcoma-associated herpesvirus-infected cells. *J Natl Cancer Inst* 2005, **97**:656-666.
289. Laman H, Coverley D, Krude T, Laskey R, Jones N: **Viral cyclin-cyclin-dependent kinase 6 complexes initiate nuclear DNA replication.** *Mol Cell Biol* 2001, **21**:624-635.
 290. Verschuren EW, Jones N, Evan GI: **The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin.** *J Gen Virol* 2004, **85**:1347-1361.
 291. Moore P: **KSHV manipulation of the cell cycle and programmed cell death pathways.** In *Human Herpesviruses* New York: Cambridge University Press; 2007:540-558.
 292. Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N: **Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins.** *Nature* 1997, **390**:184-187.
 293. Child ES, Mann DJ: **Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence.** *Oncogene* 2001, **20**:3311-3322.
 294. Kaldis P, Ojala PM, Tong L, Makela TP, Solomon MJ: **CAK-independent activation of CDK6 by a viral cyclin.** *Mol Biol Cell* 2001, **12**:3987-3999.
 295. Sugaya M, Watanabe T, Yang A, Starost MF, Kobayashi H, Atkins AM, Borris DL, Hanan EA, Schimel D, Bryant MA, Roberts N, Skobe M, Staskus KA, Kaldis P, Blauvelt A: **Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter.** *Blood* 2005, **105**:2356-2363.
 296. Chang PC, Li M: **Kaposi's sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor.** *J Virol* 2008, **82**:278-290.
 297. Friberg JJr, Kong W, Hottiger MO, Nabel GJ: **p53 inhibition by the LANA protein of KSHV protects against cell death.** *Nature* 1999, **402**:889-894.
 298. Wu FY, Tang QQ, Chen H, ApRhys C, Farrell C, Chen J, Fujimuro M, Lane MD, Hayward GS: **Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha.** *Proc Natl Acad Sci USA* 2002, **99**:10683-10688.
 299. Izumiya Y, Lin SF, Ellison TJ, Levy AM, Mayeur GL, Izumiya C, Kung HJ: **Cell cycle regulation by Kaposi's sarcoma-associated herpesvirus K-bZIP: direct interaction with cyclin-CDK2 and induction of G1 growth arrest.** *J Virol* 2003, **77**:9652-9661.
 300. Park J, Seo T, Hwang S, Lee D, Gwack Y, Choe J: **The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity.** *J Virol* 2000, **74**:11977-11982.
 301. Polson AG, Huang L, Lukac DM, Blethrow JD, Morgan DO, Burlingame AL, Ganem D: **Kaposi's sarcoma-associated herpesvirus K-bZIP protein is phosphorylated by cyclin-dependent kinases.** *J Virol* 2001, **75**:3175-3184.
 302. Lukac DM, Renne R, Kirshner JR, Ganem D: **Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein.** *Virology* 1998, **252**:304-312.
 303. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, Miller G: **A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.** *Proc Natl Acad Sci USA* 1998, **95**:10866-10871.
 304. Cannon M, Cesarman E, Boshoff C: **KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.** *Blood* 2006, **107**:277-284.
 305. Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, Silverstein RL, Rafii S, Mesri EA: **Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR.** *Cancer Cell* 2003, **3**:131-143.
 306. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, Sawai ET, Molinolo A, Gutkind JS, Montaner S: **The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.** *Cancer Cell* 2006, **10**:133-143.
 307. Montaner S, Sodhi A, Ramsdell AK, Martin D, Hu J, Sawai ET, Gutkind JS: **The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma.** *Cancer Res* 2006, **66**:168-174.
 308. Sodhi A, Montaner S, Gutkind JS: **Viral hijacking of G-protein-coupled-receptor signalling networks.** *Nat Rev Mol Cell Biol* 2004, **5**:998-1012.
 309. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS: **Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes.** *Cancer Cell* 2003, **3**:23-36.
 310. van Dyk LF, Virgin HWt, Speck SH: **The murine gammaherpesvirus 68 v-cyclin is a critical regulator of reactivation from latency.** *J Virol* 2000, **74**:7451-7461.
 311. Platt G, Carbone A, Mittnacht S: **p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma.** *Oncogene* 2002, **21**:1823-1831.
 312. Glaunsinger B, Chavez L, Ganem D: **The exonuclease and host shutoff functions of the SOX protein of Kaposi's sarcoma-associated herpesvirus are genetically separable.** *J Virol* 2005, **79**:7396-7401.
 313. Glaunsinger B, Ganem D: **Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover.** *Mol Cell* 2004, **13**:713-723.
 314. Glaunsinger B, Ganem D: **Highly selective escape from KSHV-mediated host mRNA shutoff and its implications for viral pathogenesis.** *J Exp Med* 2004, **200**:391-398.
 315. Chandriani S, Ganem D: **Host transcript accumulation during lytic KSHV infection reveals several classes of host responses.** *PLoS ONE* 2007, **2**:e811.
 316. Browne EP, Wing B, Coleman D, Shenk T: **Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs.** *J Virol* 2001, **75**:12319-12330.
 317. Ray N, Enquist LW: **Transcriptional response of a common permissive cell type to infection by two diverse alphaherpesviruses.** *J Virol* 2004, **78**:3489-3501.
 318. Carter KL, Cahir-McFarland E, Kieff E: **Epstein-barr virus-induced changes in B-lymphocyte gene expression.** *J Virol* 2002, **76**:10427-10436.
 319. Wade M, Kowalik TF, Mudryj M, Huang ES, Azizkhan JC: **E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection.** *Mol Cell Biol* 1992, **12**:4364-4374.
 320. Lembo D, Griboaud G, Cavallo R, Riera L, Angeretti A, Hertel L, Landolfo S: **Human cytomegalovirus stimulates cellular dihydrofolate reductase activity in quiescent cells.** *Intervirology* 1999, **42**:30-36.
 321. Petrik DT, Schmitt KP, Stinski MF: **Inhibition of cellular DNA synthesis by the human cytomegalovirus IE86 protein is necessary for efficient virus replication.** *J Virol* 2006, **80**:3872-3883.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

